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ABBREVIATIONS 
BNCT Boron neutron capture therapy 
BPA-F Boronophenylalanine-fructose 
BSH Boronosodiumhydrate 
CR Complete response 
CRT Chemoradiotherapy 
CT Computed tomography 
DFS  Disease-free survival 
DSS Disease-specific survival 
FCR Finnish Cancer Registry 
HPV Human papilloma virus   
IAP  Inhibitor of apoptosis proteins 
LC Local control 
LSCC Laryngeal squamous cell carcinoma 
MRI Magnetic resonance imaging 
OS Overall survival 
PET Positron emission tomography 
PR Partial response 
RFS Recurrence-free survival 
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SCC Squamous cell carcinoma 
TL Total laryngectomy 
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Laryngeal cancer is one of the most common head and neck cancers, with 
approximately 157000 new cases in the world annually. Laryngeal squamous cell 
carcinoma (LSCC), the most common histologic type (>90%), mainly affects male 
smokers. Traditionally, the treatment of early LSCC (T1-2) has been either organ-
sparing surgery or radiotherapy (RT). For advanced LSCC (T3-4), surgical treatment 
has mainly consisted of total laryngectomy (TL), i.e. complete removal of the larynx 
with resultant permanent tracheostoma and loss of laryngeal voice. To avoid the 
permanent sequelae of TL, a combination of chemotherapy and RT, 
chemoradiotherapy (CRT), is being increasingly advocated for the treatment of these 
tumors. However, it is suspected that this change in treatment paradigm might be 
behind the observed declining survival of patients with LSCC, a phenomenon noted 
particularly in the USA. Despite generally good response to the primary treatment, 
LSCC recurs in up to 30% of cases.  Furthermore, recurrence carries a high risk of 
death due to LSCC. Follow-up is pursued to detect recurrence as early as possible to 
improve outcome. Although many factors are associated with the risk of LSCC 
recurrence, no clinically applicable tools exist to aid in primary treatment decisions to 
avoid recurrence. 
 
In this study, the treatment outcome and recurrences of all patients treated for 
laryngeal cancer in Finnish university hospitals during 2001-2005 were evaluated. 
This cohort included 366 patients, which was 67% of all laryngeal cancer patients 
registered in the Finnish Cancer Registry during the study period. Of the 360 patients 
with LSCC, 342 were treated with curative intent. Treatment outcomes for glottic T1a 
LSCC were excellent, with a 5-year disease-specific survival (DSS) of 100%. In the T2 
glottic and supraglottic LSCC groups, primarily treated with RT or CRT, DSS was 
lower than generally reported in the literature (78% and 54%, respectively). CRT was 
increasingly used for T3-4 tumors, although T4 glottic tumors treated with CRT had 
poor outcome. Recurrence was observed in 22% of cases; 91% of the recurrences 
occured within 36 months of treatment. None of the patients with glottic T1a tumors 
had recurrence after 36 months, which raises the question of the role of a routine 5-
year follow-up for this patient group. WHO performance status >0, presence of neck 
metastases, and non-surgical primary treatment were significant predictors of 
recurrence. Local recurrence of glottic LSCC could be successfully salvaged. Regional 
or distant recurrence and any recurrence of supraglottic LSCC carried a poor 
prognosis. These results underline the importance of sufficiently aggressive primary 
treatment, particularly for supraglottic LSCC.  
 
Although treatment outcome with RT or CRT is mainly good, some tumors persist or 
recur after treatment. In these cases, salvage surgery—often TL—is performed. 
Currently, there are no validated tools to identify patients with radioresistant tumors 
prior to treatment. Several molecular markers have been investigated in this regard. 
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Survivin, Wrap53β, and p16INK4a could theoretically be such markers. Survivin is the 
smallest member of the inhibitor of apoptosis proteins family, which consists of 
proteins that regulate controlled cell death. Survivin is rarely expressed in normal 
tissues, whereas its expression is abundant in cancers. It has been associated with 
increased tumor radioresistance in some studies. On the other hand, others have 
recognized it as a marker for improved outcome. The Wrap53 gene partially overlaps 
the p53 tumor suppressor gene. Antisense RNA produced by this gene regulates the 
function of the p53 gene. Wrap53β, one of the protein products of the Wrap53 gene, 
participates in DNA double-strand break repair and telomere elongation, which are 
mechanisms that ensure genomic stability. Disruption of Wrap53β is associated with 
dyskeratosis congenita, a condition that predisposes to multiple malignant tumors in 
the head and neck area. Decreased nuclear expression of this protein is associated 
with poor treatment outcome in many cancers. The expression of p16INK4a, a marker 
used as a surrogate for human papillomavirus infection, is associated with improved 
outcome in oropharyngeal squamous cell carcinoma. However, a similar link to 
treatment outcome has not been established for LSCC.  
 
Based on the observed inferior outcome for T2 LSCC in Finland, the aforementioned 
markers were investigated in a Finnish-Swedish cohort of 149 patients treated with 
RT or CRT for T2N0M0 or T3N0M0 glottic LSCC to find factors that could predict 
recurrence. No significant findings regarding survivin were detected, although a 
trend towards better disease-free survival (DFS) for patients with strong nuclear 
survivin expression was observed. Regarding Wrap53β, predominantly cytoplasmic 
expression was associated with poorer DFS and a trend for poorer overall survival 
was also observed in this group. P16INK4a expression was rare in LSCC patients (7%) 
and more common among patients under the age of 60. In this younger patient 
group, none of the patients with p16INK4a expression experienced tumor recurrence. 
DFS was significantly better in this patient group as well.  
 
Patients with LSCC recurrence after RT or CRT have only one standard option for 
salvage, which is surgery. While small recurrences may be salvaged with organ-
sparing surgery, TL is often the only option. Non-surgical salvage options are being 
investigated, one of which is boron neutron capture therapy (BNCT). In BNCT, a non-
radioactive boron, B10, commonly in a compound of boronophenylalanine-fructose 
(BPA-F), is infused intravenously. This substance has a tendency to accumulate 
preferably in tumor cells. After infusion, the tumor is irradiated with epithermal 
neutrons. This leads to the boron neutron capture reaction, which releases lethal 
doses of radiation within the cells containing BPA-F. BNCT has the ability to deliver 
high doses of radiation to the tumor with low toxicity to surrounding tissues.    
 
In the current study, a group of nine patients who were treated with one or two 
fractions of BNCT for LSCC persisting or recurring after primary RT or CRT was 
examined. In addition to response and toxicity evaluation, the potential of BNCT as a 
larynx-sparing salvage treatment was evaluated. Of the eight evaluable tumors, six 
(75%) responded to BNCT. No serious (Grade 4-5) toxicity was encountered. Despite 
Abstract 
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good primary responses, only one patient was permanently cured with a preserved 
larynx. With treatment intensification and dose optimization, BNCT could show 
potential as a larynx-sparing treatment.  
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SUMMARY IN FINNISH 
Kurkunpääsyöpä on yksi yleisimmistä pään ja kaulan alueen syövistä. Maailmassa 
todetaan vuosittain noin 157000 uutta kurkunpääsyöpää. Yleisin syöpätyyppi on 
levyepiteelikarsinooma (>90%), ja siihen sairastuvat ovat useimmiten tupakoivia 
miehiä. Varhaisen vaiheen (T1-2) syövän hoitona on perinteisesti ollut joko 
kurkunpäätä säästävä kirurgia tai sädehoito. Myöhäisen vaiheen (T3-4) syövän 
kirurginen hoito on useimmiten vaatinut kurkunpään poiston. Tässä leikkauksessa 
muodostetaan pysyvä henkitorviavanne eikä potilas pysty enää tuottamaan 
luonnollista ääntä. Näiden haittojen välttämiseksi sädehoidon ja solusalpaajahoidon 
yhdistelmää, kemosädehoitoa, on lisääntyvässä määrin käytetty kurkunpään poiston 
vaihtoehtona. Hoitolinjan muutoksen on epäilty olevan huononevien hoitotulosten 
syynä etenkin Yhdysvalloissa. Vaikka kurkunpääsyövän hoitovaste onkin useimmiten 
hyvä, uusiutuu syöpä jopa 30%:lla potilaista. Uusiutumisen riskitekijöitä on 
tunnistettu, mutta niiden soveltuvuudesta hoitopäätöksiä ohjaaviksi tekijöiksi ei vielä 
ole tarpeeksi tutkimustietoa. Uusiutumiseen liittyy suuri syöpäkuoleman riski.  
Syöpäpotilaita seurataan hoidon jälkeen, jotta uusiutumat havaittaisiin 
mahdollisimman varhain, jolloin niiden hoito on tuloksellisinta.  
 
Tutkimuksessa selvitettiin vuosina 2001-2005 kaikkien 366:n Suomen 
yliopistollisissa keskussairaaloissa hoidetun kurkunpääsyöpäpotilaan hoitotulokset ja 
syövän uusiutumien erityispiirteet. Levyepiteelisyöpä todettiin 360 potilaalla. Näistä 
342:lla hoidon tavoite oli parantava. Äänihuulen pienten, T1a syöpien hoitotulokset 
olivat erinomaiset: yksikään potilaista ei kuollut kurkunpääsyöpään, vaikka tauti 
uusiutuikin 11%:lla potilaista. T2 luokan syövät hoidettiin pääasiassa sädehoidolla tai 
kemosädehoidolla. Näiden potilaiden ennuste oli huonompi kuin on yleisesti 
raportoitu: äänihuulisyöpäpotilaiden 5-vuotiselossaoloennuste oli 78% ja äänihuulen 
yläpuolista syöpää sairastavien potilaiden 54%. Kemosädehoitoa käytettiin usein 
kookkaampien T3-4 syöpien hoidossa, mutta T4 luokan äänihuulisyövissä 
hoitotulokset tällä menetelmällä olivat erittäin huonot.  Syövän uusiutuma todettiin 
22%:lla potilaista. Uusiutumista 91% havaittiin 36kk sisällä hoidon päättymisestä. 
Yksikään T1a syöpä ei uusiutunut 36kk seurannan jälkeen ja tämän ryhmän kohdalla 
rutiininomaisen viiden vuoden seurannan mielekkyys voidaan kyseenalaistaa. 
Merkittäviä uusiutuman riskitekijöitä olivat  WHO:n suorituskykyluokka >0, kaulan 
etäpesäkkeet alkuvaiheessa ja ei-kirurginen hoito. Paikallisesti uusiutuneen 
äänihuulisyövän hoitotulokset olivat hyvät. Ennuste oli hyvin huono, mikäli tauti 
uusiutui muualla kuin paikallisesti tai alkuperäinen kasvain oli ollut äänihuulitason 
yläpuolella. Nämä tulokset osoittavat, että erityisesti äänihuulitason yläpuolisia 
syöpiä tulee hoitaa aggressiivisesti. 
  
Vaikka sädehoidon ja kemosädehoidon tulokset ovatkin useimmiten hyvät, osa 
kasvaimista ei reagoi hoitoon tai uusiutuu myöhemmin. Tällaisissa tapauksissa 
edetään kirurgiaan, jolloin leikkauksessa useimmiten poistetaan koko kurkunpää. 
Summary in Finnish 
12 
Toistaiseksi ei ole olemassa keinoja tunnistaa huonosti sädehoidolle reagoivia 
kasvaimia ennen hoitoa. Monia molekyylaarisia ennustetekijöitä on tutkittu, ja 
teoriassa tällaisia ennustetekijöitä voisivat olla mm. survivin, Wrap53β ja p16INK4a. 
Survivin kuuluu ohjelmoidun solukuoleman estäjiin ja on tämän ryhmän pienin 
proteiini. Survivin esiintyy harvoin terveissä soluissa, mutta sen esiintyvyys on 
runsasta syöpäsoluissa. Survivinia koskevat tutkimustulokset ovat ristiriitaisia: 
toisissa tutkimuksissa survivin on yhdistetty huonoon sädehoitovasteeseen ja toisissa 
se näyttäisi ennustavan parempaa hoitotulosta. Wrap53-geeni sijaitsee osin 
solusykliä keskeisesti säätelevän p53-tuumorisupressorigeenin kanssa päällekkäin, ja 
siitä p53 geenin lukusuuntaan nähden vastakkaiseen suuntaan tuotettava ns 
antisense-RNA säätelee p53-geenin toimintaa. Wrap53β, yksi Wrap53-geenin 
tuottamista proteiineista, osallistuu DNA:n kaksoiskierteen katkosten korjaamiseen 
ja telomeerien pidentämiseen. Nämä mekanismit tukevat solun geneettistä vakautta. 
Wrap53β:n toiminnan häiriintyminen on yhdistetty dyskeratosis congenitaan, 
sairauteen, joka altistaa useille pään ja kaulan alueen syöville. Tämän proteiinin 
vähäisempi esiintyminen tumassa on yhdistetty huonompaan ennusteeseen useissa 
syövissä. Papilloomavirustulehduksen sijaismerkkiaineen, p16INK4a:n, esiintymisen 
on todettu liittyvän suunielun syövän parempaan hoitoennusteeseen. Tällaista 
kytköstä ei ole kuitenkaan havaittu kurkunpääsyövissä.  
 
T2 potilaiden huonon hoitotuloksen vuoksi edellä mainittuja merkkiaineita tutkittiin 
suomalais-ruotsalaisessa 149 sädehoidetun T2NoMo-T3N0Mo äänihuulisyöpä-
potilaan aineistossa uusiutumaa ennustavien tekijöiden löytämiseksi. Survivin ei 
tuottanut merkitseviä tuloksia, vaikka syövättömän elossaolon ennuste olikin 
parempi niillä potilailla, joiden kasvainsolujen tumat ilmensivät tätä proteiinia 
voimakkaasti. Wrap53β:n solulimaan painottuva esiintyminen taas ennusti 
lyhyempää tautivapaata elossaoloa ja taipumusta lyhyempään elossaoloon ylipäätään.  
P16INK4a esiintyi harvoin kurkunpääsyövässä (7%:lla). Sen esiintyminen oli 
yleisempää alle 60-vuotiailla. Tauti ei uusiutunut niillä alle 60-vuotiailla potilailla, 
joilla proteiini ilmentyi, ja heillä myös syövättömän elossaolon ennuste oli parempi.  
 
Jos kurkunpääsyöpä uusiutuu sädehoidon tai kemosädehoidon jälkeen, ainoana 
parantavana hoitovaihtoehtona on pidetty kirurgiaa. Pienet uusiutumat voidaan 
leikata kurkunpäätä säästäen hyvin tuloksin. Useimmiten ainoaksi vaihtoehdoksi jää 
kuitenkin koko kurkunpään poisto. Tälle toimenpiteelle on etsitty vaihtoehtoja. Yksi 
tutkimuksen kohteista on boorineutronikaappaushoito (BNCT). BNCT:ssa ei-
radioaktiivista booria, yleensä booriyhdisteenä (esim. boorifenyylialaniini-fruktoosi), 
annetaan potilaalle suonensisäisesti. Tällä yhdisteellä on taipumuksena hakeutua 
erityisesti kasvainsoluihin. Infuusion jälkeen kasvainta sädetetään neutroneilla. 
Sädetys johtaa boorineutronikaappausreaktioon, jossa soluihin kerääntynyt boori 
hajoaa vapauttaen kuolettavan määrän säteilyä. BNCT:n avulla voidaan antaa suuri 
sädeannos kasvaimeen ja toisaalta samalla minimoida haittavaikutukset ympäröiviin 
kudoksiin. BNCT:a on tutkittu erityisesti uusiutuneiden, kirurgisen hoidon 




Tutkimuksessa annettiin BNCT-hoitoa yhdeksälle potilaalle, joiden kurkunpääsyöpä 
ei ollut reagoinut sädehoitoon tai kemosädehoitoon tai joiden tauti oli uusiutunut 
hoidon jälkeen. Potilaat saivat 1-2 BNCT-annosta. Hoitovasteen lisäksi arvioitiin 
hoidon haittavaikutuksia ja sitä, voisiko BNCT olla elintä säästävä hoitovaihtoehto 
kurkunpään poistolle. Hoitovaste saatiin arvioitua kahdeksalla potilaalla, joista 
kuuden (75%) kasvain reagoi BNCT:lle. Vaikka kasvaimet reagoivatkin hoitoon, vain 
yhden potilaan syöpä parani pysyvästi BNCT:lla ilman kurkunpään poistoa. Vakavia 
haittavaikutuksia ei havaittu. BNCT saattaisi olla vaihtoehtoinen kurkunpäätä 







Laryngeal cancer is one of the most common head and neck cancers in the world, 
with an incidence of 157000 new cases each year (1). Tobacco smoking is the main 
known risk factor; nine out of 10 patients with this cancer type are smokers. 
Laryngeal cancer mostly affects males, with a male to female ratio of 9:1 
(www.cancerregistry.fi). The most common histologic subtype is laryngeal squamous 
cell carcinoma (LSCC).  
 
LSCC is classified according to its localization into glottic, supraglottic, and subglottic 
tumors. Glottic tumors comprise the majority of LSCCs (approximately 70%), 
followed by supraglottic (approximately 25-30%) cancer. Subglottic tumors are rare, 
comprising approximately 1-2% of LSCCs. The diagnosis of LSCC is based on 
histological examination of the tumor tissue, usually acquired through 
laryngomicroscopy under general anesthesia. Clinical examination and radiological 
imaging are utilized to assess the local extent and metastatic spread of the disease.  
 
The treatment of LSCC depends on the site of presentation and tumor size, as well as 
the extent of local and metastatic spread. When distant metastases are absent, as in 
most cases, treatment is generally given with curative intent. Early stage tumors (T1-
2) may be treated with either organ-sparing resection (transoral laser surgery [TLS] 
or open partial resection) or radiotherapy (RT). Locally advanced tumors (T3-4) 
require either chemoradiotherapy (CRT) or total laryngectomy (TL), i.e. the removal 
of the larynx and creation of a permanent tracheostoma, followed by postoperative 
RT. Treatment of the neck metastases in advanced disease is dependent on the 
primary treatment. When oncological treatment is chosen, the neck is also irradiated 
(neck dissection and TL reserved for salvage treatment if needed). If TL is performed, 
neck dissection is performed simultaneously when indicated.  
 
In the recent decades, the use of CRT instead of radical surgery has increased in the 
treatment of LSCC. Some landmark prospective studies (2,3) have established CRT as 
a viable alternative for TL with similar survival outcomes. The aim of laryngeal 
preservation has, however, raised questions in the light of worsening treatment 
outcomes in some patient groups in USA cancer registry data (4). In Finland, the era 
of CRT in the treatment of LSCC began in the late 1990s. Detailed national 
information on treatment results has previously been lacking.  According to data 
from the combined cancer registry of the Nordic countries (NORDCAN) (5), 
treatment results seem to be improving slowly in contrast to the data from the USA, 
where outcomes are stable or even worsening in some subclasses (4,6). 
 
There are currently no means to forecast the outcome of primary oncological 
treatment in LSCC. However, several factors, such as poor general health (7,8), 
smoking continuation (9), supraglottic tumor localization (10), and higher T class or 
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stage (11) are associated with increased risk of recurrence. Treatment intensification 
(e.g. CRT instead of RT) in patients with known high risk of recurrence could prove 
advantageous and reduce the need for radical surgery later. On the other hand, 
treatment deintensification in patients with a lower risk of recurrence could 
potentially diminish the long-term adverse sequelae of treatment. Several molecular 
factors have been suggested to indicate tumor radioresistance and oncological 
treatment failure. Among these factors, inhibitor of apoptosis proteins (IAP) has been 
one of the study targets. Survivin, the smallest member of this family, regulates cell 
division and apoptosis. High nuclear expression of survivin has been demonstrated to 
lead to RT failure in in vitro studies (12) as well as in clinical patient series. Wrap53β  
is a coding product of the Wrap53 gene, which partially overlaps the tumor 
suppressor p53 gene. The functions of Wrap53β include intracellular translocation of 
different factors (e.g. telomerase and splicing factors) to so-called Cajal bodies, which 
are sub-organelles found in the nucleus. Cajal bodies manufacture RNA that is 
required to add nucleotides to the telomere ends by telomerase enzymes. Wrap53β 
has recently been studied as a potential predictor of RT response. High nuclear 
expression of Wrap53β has been observed as a predictor of good RT response in head 
and neck cancer (13). Human papilloma virus (HPV) infection and its surrogate 
marker, p16INK4a expression, have been identified as predictors of favorable outcome 
in oropharyngeal carcinoma. HPV/p16INK4a positivity is rare in LSCC (14), and its 
etiologic role and prognostic potential are not well understood in this cancer type 
(15).  
 
Despite good primary response to treatment, recurrence of LSCC is common. In the 
case of recurrence after primary RT/CRT, treatment options are few. Small recurrent 
tumors can be salvaged with TLS or open partial resection (16). TL is, however, often 
the only option for salvage. TL results in the loss of laryngeal voice and the 
introduction of a permanent tracheostoma. Reirradiation has been investigated as a 
potential curative treatment option in recurrent head and neck SCC. Due to the 
associated high risk of serious toxicity, it is not widely advocated in treatment 
protocols. New, less toxic, more targeted forms of RT for recurrence are being 
investigated. One example of these is boron neutron capture therapy (BNCT), an 
experimental therapy based on the extremely short-range radiation produced by 
boron neutron capture reaction. This therapy ideally only harms the cells uptaking 
boron, thus minimizing the radiation dose to the surrounding non-cancerous tissues 
(17). 
 
The present study aims to evaluate the site distribution, treatment, and prognosis of 
LSCC in Finland as well as to assess both the clinical and molecular factors predicting 
treatment outcome and the risk of recurrence. The effectiveness of recurrent cancer 
treatment and, specifically, the safety and efficacy of BNCT in the management of 
recurrent LSCC are also investigated. 
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 LARYNGEAL CANCER – GENERAL CONSIDERATIONS 
2.1.1 EPIDEMIOLOGY AND RISK FACTORS 
 
Laryngeal cancer is the 21st most common cancer worldwide, comprising 1.1% of all 
new cancers. Men are more prone to laryngeal cancer; 1.9% of all new cancers in men 
are found in the larynx whereas for women the figure is significantly lower (0.3%). 
Variability exists between different geographical regions regarding incidence. In 
developing countries, the age-adjusted incidence in 2012 was 3.5 per 100000, as 
opposed to 5.1 in more developed countries. (18) In Finland, the incidence of 
laryngeal cancer has declined over the last decades in men from the 1968-1972 high 
point of 6.7 per 100000 to 2.1 in 2014. A decrease in females was also observed, from 
0.4 to 0.2 (www.cancerregistry.fi).  
 
Smoking  (19) and alcohol consumption  (20) are widely recognized as the main risk 
factors for the development of laryngeal cancer. Together, their effect on cancer risk 
is multiplicative (21). The decline in laryngeal cancer incidence and mortality has 
followed the declining trend in smoking in many countries (4,22,23).  
2.1.2 HISTOLOGY AND CLASSIFICATION  
 
Squamous cell carcinoma (SCC) comprises the vast majority (over 90%) of laryngeal 
carcinomas (24,25). Other rarely reported histologies include salivary gland type 
carcinomas  (26), e.g. adenoid cystic carcinoma  (27), and mucoepidermoid 
carcinoma  (28) as well as non-epithelial cancers including sarcomas  (29) and 
melanoma  (30). Lymphoid malignancies also rarely occur in the larynx  (24). 
 
LSCC is staged according to the tumor, node, metastasis (TNM) classification 
updated by UICC and AJCC (Table 1) (31). The larynx is divided into three regions, 
namely the glottic (the vocal cords), supraglottic (above the vocal cord level), and 
subglottic regions (starting from 1 cm below the upper surface of the vocal folds). If 
the tumor grows into multiple regions, the region with the highest tumor volume is 
defined as the origin. Although lacking an official definition, the term “transglottic” is 
widely used in clinical medicine to describe tumors extending both above and below 





Table 1. Clinical TNM classification of LSCC according to UICC, 7th edition  (31)  
Stage, all subsites  
T1 N0 M0 
T2 N0 M0 
T3 N0 M0 
T1-3 N1 M0 
T4a N0 M0 
T1-4a N2a-c M0 
T4b N0-2c M0 
any T N3 M0 
any T any N M1 
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Distinguished from other malignant tumors, the TNM classification of LSCC includes 
a functional parameter, i.e. vocal cord mobility to discriminate between T1, T2, and 
T3 glottic carcinomas and T2 and T3 supraglottic carcinomas. Vocal cord mobility is 
determined by subjective evaluation and interpretation. Contrary to most other head 
and neck tumors, the diameter of the tumor in itself is not a defining characteristic 
for classification. Rather, the involvement of adjacent structures defines the tumor. 
These properties of LSCC TNM classification have raised debates on the feasibility 
and reproducibility of this classification for its complexity (32-35). Imaging with 
computerized tomography (CT) or magnetic resonance imaging (MRI) brings 
precision to classification, although peritumoral inflammation often complicates the 
precise assessment of tumor infiltration, particularly the involvement of cartilage  
(36,37). 
2.1.3 CLINICAL PRESENTATION AND DIAGNOSTIC WORKUP 
 
Laryngeal cancer patients typically present with symptoms of hoarseness and sore 
throat. As the tumor grows, more severe symptoms including dyspnea and dysphagia 
may follow (38). The presenting symptoms are dependent on the primary tumor 
localization. Tumors of the glottic region typically present with hoarseness, whereas 
supraglottic tumors typically present with pressure symptoms such as lump in the 
throat or throat pain. Due to the early presentation of hoarseness, glottic tumors are 
generally detected at an earlier stage than supraglottic tumors (24,38,39).  
 
When a patient presents in the outpatient clinic with a suspected laryngeal tumor, a 
thorough ENT workup including clinical examination as well as fiberoscopic 
investigation with or without the use of narrow-band imaging (NBI) (40) is 
conducted. Videolaryngoscopy with stroboscopy may be performed to obtain 
information on the function and vibrating properties of the affected vocal cord and 
thus the depth of invasion of the tumor. After clinical examination, an endoscopic 
evaluation of the tumor and the surrounding hypopharynx and esophagus under 
general anesthesia is scheduled to obtain biopsies of the tumor and to assess the 
extent of tumor growth for therapeutic decision-making. The biopsies are examined 
by a pathologist to confirm cancer diagnosis. Imaging should encompass the larynx 
and the neck for assessing the extent of the primary tumor. Imaging of the chest 
(either with conventional x-ray or CT scan) should also be performed to rule out the 
presence of distant metastases or synchronous primary lung tumors. For T1a glottic 
tumors, clinical assessment of the primary tumor and the neck and a chest x-ray are 
usually sufficient for evaluation. 
2.1.4 TREATMENT AND PROGNOSIS  
 
Treatment of the primary tumor in LSCC depends on its localization and clinical 
stage. Generally, monotherapy with surgery or RT is preferred for early T class (T1-2) 
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tumors. With increasing tumor size, CRT or radical surgery combined with post-
operative RT or CRT may be advocated.  
 
TLS was introduced in the late 1980s as a curative treatment option for LSCC. In 
1993, Steiner presented his series of 240 patients treated with TLS including neck 
dissection when indicated (41). The study included a group of 180 patients with 
glottic Tis-T2 LSCC with normal vocal cord mobility. For this population, local 
failures were only encountered in 6% of patients and the 5-year OS and disease-
specific survival (DSS) were 87% and 100%, respectively.  Several authors have later 
reported similar, excellent outcomes with TLS for early (T1-2) glottic LSCC patients  
(42-46).  
 
RT is also considered a valid treatment choice for early glottic LSCC. A Dutch group 
reported a large retrospective institutional series of 1050 T1-2N0 LSCC patients (47). 
In their series, 5-year local control (LC) and disease-free survival (DFS) and OS were 
85% and 81%, respectively. Several authors presented similar oncological results with 
5-year DSS rates of 94%-96% for T1 patients and 82-90% for T2 patients  (48-52). 
More recently, RT and CRT were compared in retrospective studies regarding 
oncological results in the treatment of early glottic carcinomas (particularly in case of 
T2 tumors), showing improved laryngeal preservation and DFS, but not OS, in the 
CRT group  (53-56). 
 
Several research groups performed retrospective comparisons comparing TLS and RT 
in T1a patients. Mahler et al. presented a series of 351 patients (57). In their series, 
RT was administered for T1a patients during 1986-1996 and TLS during 1996-2005. 
In their study, 5-year DSS for RT and TLS patients was similar (97 vs. 98%), whereas 
the relative risk for later TL was 12.7 fold in the RT group. Similar findings regarding 
laryngeal preservation were reported by Schrijvers et al.  (58), although patients with 
deeper infiltrating tumors were excluded from their study.  Prospective, randomized 
studies comparing oncological results are lacking. A meta-analysis by Abdurehim et 
al. (59) reported no difference in oncological results and voice outcome measures 
between the studies, although patients treated with TLS had a higher laryngeal 
preservation rate. A recent Cochrane review (60) revealed only one randomized 
controlled trial comparing surgery (open partial resection) and RT for the treatment 
of early LSCC, concluding that evidence for reliable comparisons is lacking. 
Regarding voice outcomes, only one randomized trial comparing RT with TLS exists  
(61), presenting slightly less breathiness and a smaller post-treatment glottal gap in 
patients treated with RT.  
 
The treatment of the primary tumor in early supraglottic LSCC is similar to that of 
early glottic LSCC. However, neck metastases are very common in early supraglottic 
carcinoma due to more abundant lymphatic drainage of the area compared to the 
glottic tumors. Therefore, the management of the neck with either elective neck 
dissection or RT/CRT is mandatory. In the case of a clearly unilateral primary tumor, 
Review of the literature 
20 
ipsilateral neck treatment may be performed. In the case of centrally or bilaterally 
located tumors, bilateral neck treatment is recommended (62). 
 
TL has been the gold standard for the management of advanced LSCC (both glottic 
and supraglottic) since 1873 when Billroth performed the first procedure (63). 
Despite its oncological virtues, TL results in a permanent tracheostoma and the loss 
of laryngeal voice, thus permanently affecting the quality of life of the patient  
(64,65). In the 1990s, an interim report of the Veterans’ Affairs (VA) study (2), the 
first prospective, randomized trial comparing TL to definitive oncological treatment, 
was published. In their study of 332 patients, induction chemotherapy followed by RT 
resulted in equal survival compared to TL but with laryngeal preservation. However, 
local recurrences were more common after non-surgical treatment. The study did not 
include a formal laryngeal function assessment. Since the VA study, numerous 
retrospective studies comparing TL and RT/CRT have been published. The majority 
of them show no difference in survival outcome between treatments (66-70). Some 
claim surgical treatment to be associated with improved survival for T3 tumors  
(71,72), while others have found this to be true only for T4 tumors (73,74). According 
to some studies, surgical treatment is associated with improved locoregional control  
(66,67,69). However, no additional randomized trials have been presented after the 
VA study, possibly due to the ethical constraints on conducting such studies in the 
presence of evidence of comparable survival outcomes with either treatment. 
Concerns on the feasibility of oncological treatment for advanced laryngeal cancer 
have been raised due to the declining survival of laryngeal cancer patients in the USA 
synchronous to the change in treatment protocols (4,75-77) 
  
In Finland, LSCC treatment follows uniform national guidelines set and updated by 
the Finnish Head and Neck Oncology Working Group. The local head and neck tumor 
boards are responsible for the implementation of this protocol, and may decide to 
deviate from it with due cause.   
 
The guidelines for the treatment of LSCC in Finland are as follows: 
 
Glottic carcinoma: T1-2 tumors may be treated with either TLS or RT. CRT is 
preferred for young T2 patients and patients with large T2 tumors. Treatment of the 
neck (surgical or oncological) is not necessary for T1-2N0 glottic tumors. For T3 
tumors, the primary treatment of choice is CRT (TL as an alternative treatment 
option). TL is the treatment of choice for T4 tumors. Neck dissection is performed 
only in case of clinical neck metastasis for T2-3 tumors and electively for all T4 
tumors.  
 
Supraglottic carcinoma: T1N0 tumors may be treated with TLS or RT without neck 
dissection. For T2-4 tumors, CRT is the treatment of choice, with surgery as an 
alternative option (TLS for T2 tumors, TL for T3-4 tumors). If surgery is chosen, neck 
dissection is warranted. With CRT, salvage neck dissection is performed only if 




Subglottic tumors (rare): Either CRT or TL is used.  
 
For all LSCCs, post-operative oncological treatment follows the same 
recommendations: RT is administered to all patients with T3-4 tumors treated with 
surgery and to all patients with a single nodal metastasis. CRT is given if the primary 
surgical margins are positive, if more than one pathological metastasis in the neck is 
detected, or if any of the metastatic nodes present extracapsular growth.  
 
Some variability exists between different national guidelines. For example, the 
Danish DAHANCA guidelines  (78) advocate the primary use of definitive non-
surgical treatment for all LSCC patients, except for those with extensive tumors with 
remarkable thyroid cartilage invasion. For T1a glottic LSCC, TLS is also an alternative 
option to RT. In Sweden, the national guidelines resemble those from Finland, with 
some exceptions. CRT is not administered to patients with T2 glottic or supraglottic 
tumors; CRT is not an alternative to TL in supraglottic T4 tumors (79). In 2006, the 
American Society of Clinical Oncology published their guidelines for the use of 
larynx-sparing strategies in the management of LSCC (80). The main difference 
compared to the Finnish recommendation is the preference for open organ-sparing 
surgery over TLS for T2 glottic and T1-2 supraglottic tumors. In the 21st century, open 
partial resection has rarely been utilized for the management of LSCC in Finland, 
possibly due to the risk of morbidity and complications associated with increased 
aspiration risk. The National Comprehensive Cancer Network (NCCN) 2014 
guidelines  (81) comply with the Finnish guidelines, with the exceptions of induction 
chemotherapy followed by RT or surgery as an alternative for T3 and selected T4 
tumors (not advocated in Finland), and CRT not being an option for larger T2 
tumors.   
 
The general prognosis of LSCC is modest, with a reported 5-year relative survival rate 
of 60-65%  (82-84). However, there seem to be distinct subgroups of LSCC with 
differing clinical courses and outcomes. Glottic T1 LSCC represents one of these 
distinct groups with 5-year OS figures commonly exceeding 90%. Curative treatment 
intent is feasible for the vast majority of LSCC patients, excluding patients with 
distant metastases and generally patients with extremely extensive primary tumor 
(T4b) or nodal metastasis (N3).  
2.2 LARYNGEAL SQUAMOUS CELL CARCINOMA 
RECURRENCE 
2.2.1 POST-TREATMENT FOLLOW-UP 
 
The aim of head and neck cancer follow-up is to enable the early detection of loco-
regional recurrences as well as detection of second primary tumors (85). A recent 
Review of the literature 
22 
recommendation by the European Laryngological Society for the follow-up of LSCC 
patients expanded this list of aims to include the evaluation of treatment response, 
monitoring and management of complications, optimization of rehabilitation, 
promotion of smoking cessation and cessation of excessive alcohol consumption, 
psychosocial support to patients and their families, and patient counseling and 
education  (86). The society recommends a risk stratification-based follow-up 
program. Stage I and II tumors are considered low risk tumors and Stage III 
intermediate risk tumors, both with a recommended total follow-up duration of five 
years. Stage IV tumors are considered high-risk tumors and warrant a 10-year follow-
up according to this recommendation. If the patient presents with a second primary 
tumor during follow-up, a life-long follow-up is recommended. Regarding the 
frequency of follow-up, bimonthly follow-up is recommended for the first two years 
and quarterly to biannual follow-ups for the remaining years. Longer follow-up 
intervals may be considered for some low-risk tumors (e.g. T1a glottic LSCC treated 
with TLS with clear margins). Currently, no evidence exists regarding the ideal 
frequency and length of post-treatment follow-up in LSCC. In Finland, generally, 
quarterly follow-up visits are recommended for the first post-treatment year, 3-4 
month follow-up intervals for the second year, and biannual visits thereafter until five 
years have passed since treatment completion.  
2.2.2 RISK FACTORS FOR RECURRENCE 
 
Several factors have been suggested to predict LSCC recurrence. These factors may be 
related to diagnostic delay, patient factors, tumor characteristics, and choice of 
treatment and its implementation.  
 
Teppo et al. investigated the impact of diagnostic delay on LSCC recurrence in 
Finnish patients (87). They identified professional delay (i.e. the time from the first 
doctor’s appointment at the primary health care to diagnosis of LSCC) of one year or 
longer as an independent predictor of local and regional failure. Of head and neck 
cancer patients, LSCC patients are prone to longer diagnostic delays than patients 
with SCCs of other sites, and these delays seem to have an impact only on LSCC 
treatment outcome (88).  
 
Brandstorp-Boesen et al. (89) observed an increased risk of recurrence in younger 
patients (age under 70 years). Of patient-related factors, poor general health has also 
been identified as a predictor of recurrence (7,8). Additionally, in a series of 117 
patients with T1-T2N0 glottic LSCC (90), low pre-treatment hemoglobin reduced 5-
year locoregional control after definitive RT. Patient lifestyle may also increase the 
risk of recurrence. Smoking continuation during RT was identified as an independent 
predictor of local recurrence in a Dutch study of 549 T1a glottic LSCC patients  (9). 
 
Tumor factors play a significant role in the risk of recurrence. In a study by Johansen 
et al. (10), supraglottic tumors were more prone to recurrence compared to glottic 
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tumors. This finding was also observed by Brandstorp-Boesen et al. (89). Another 
study of 5001 patients from Denmark  (11) noted an increase in recurrence with 
increasing tumor T class and stage in glottic LSCC patients. The local extent of the 
tumor also seems to affect the risk of recurrence; anterior commissure involvement is 
associated with local failure in some studies  (91,92). Nodal metastasis at 
presentation has also been shown to predict recurrence, particularly later distant 
metastasis  (93-95). 
  
Although conclusive evidence is somewhat lacking, the choice of treatment has also 
been shown to affect the risk of recurrence in some studies, which have shown an 
association between non-surgical treatment of Stage III-IV LSCC and increased risk 
of local recurrence (2,66,67,69). The success of treatment implementation may also 
affect later tumor control. Treatment gaps reduce the effect of RT and have been 
shown to predispose patients to recurrence in some studies (96-98). Regarding 
surgical details, some studies have identified preoperative tracheotomy (99,100) and 
positive resection margins (99-101) as risk factors for recurrence. 
2.2.3 TIME AND PATTERNS OF RECURRENCE 
 
Despite successful primary treatment, LSCC recurrence is fairly common. The 
reported incidence generally varies around 16-30% (11,102-104). Most of the 
recurrences occur within the first 2-3 years after treatment (11,105-108). Some new 
cancer events may occur remarkably later. Lester et al. (109) examined a group of 61 
patients with LSCC. They observed that 85% of the recurrences occurred within 1.4 
years, and 90% occurred within 3.5 years of treatment completion. However, 
recurrences were detected as late as 6.6 years into follow-up. The stage of the tumor, 
whether early or advanced, had no impact on the time to recurrence. Another study 
including 404 patients treated with TLS for T1a glottic LSCC reported a somewhat 
longer median time to recurrence (34 months). The latest recurrence in this study 
was observed 131 months after treatment. The most prevailing mode of recurrence in 
LSCC is local recurrence (11,107,110,111). A Danish study by Lyhne et al. (11) reported 
a 30% recurrence rate for glottic LSCC patients treated with RT. Out of the 
recurrences observed, 93% were local, 11% were regional, and 5% were distant.  
2.2.4 TREATMENT AND PROGNOSIS  
 
In case of tumor persistence or recurrence, cure may still be attempted by salvage 
treatment, i.e. another treatment with a curative aim. For LSCC recurrence after 
initial surgical monotherapy, RT, CRT, and repeated surgery remain salvage options. 
With the changes in primary treatment paradigm favoring organ-sparing oncological 
treatment, an increasing number of patients with recurrent tumors have already 
undergone RT or CRT, thus making surgical treatment the only standard treatment 
available. In small recurrent tumors, organ-sparing surgery may be attempted, 
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including TLS and open partial resections. With more advanced recurrences, TL 
remains the most reliable standard treatment (112). 
 
For inoperable recurrent tumors, reirradiation may be considered in an attempt for 
cure, although one should bear in mind the high risk of complications associated with 
high cumulative radiation doses. Brachytherapy and proton therapy have also been 
proposed for recurrent head and neck cancer (113,114), although studies on LSCC are 
lacking. The standard therapy for recurrent, inoperable tumors is palliative 
chemotherapy.      
2.2.4.1 Partial laryngeal surgery  
 
For small, localized recurrences of LSCC, laryngeal preservation surgery is an option 
in a carefully selected group of patients. Several absolute or relative contraindications 
for partial laryngectomy have been suggested: arytenoid fixation, interarytenoid 
invasion, bilateral impairment of vocal cord mobility, contralateral extension of the 
disease greater than 3mm, preepiglottic extension, remarkable subglottic extension, 
thyroid or cricoid cartilage invasion, or extralaryngeal spread of the recurrent tumor  
(112,115). Patient comorbidities, including pulmonary problems, may also hinder the 
use of conservative surgery as almost all patients undergoing conservation surgery 
experience at least temporary aspiration after the procedure, exposing them to the 
threat of severe pulmonary complications.  
 
Ramakrishnan et al. explored the role of TLS in the management of recurrent LSCC 
in a systematic review and meta-analysis (116). They identified 11 studies with a total 
of 249 patients who had received TLS for recurrent laryngeal cancer. Primary Tis-T2 
tumors formed 92% of the included patients. The pooled LC after repeated TLM was 
64%. When taking into account the patients who later underwent salvage TL for 
recurrence, LC was 88%. The 2-year pooled OS was 75% with a mean larynx-sparing 
rate of 72%. With such excellent outcomes, TLS remains a viable option for salvage 
treatment for limited local recurrences. 
2.2.4.2 Salvage total laryngectomy 
 
Salvage TL has produced favorable outcome in several studies. In the landmark 
RTOG 91-11 study of 517 patients (3), Weber et al. (117) examined a subgroup of 129 
patients (25%) who underwent salvage TL. TL was performed due to disease 
progression/recurrence (63%), inadequate treatment response (29%), or functional 
problems. The majority of the patients (81%) had had a pre-treatment T class of T3 or 
higher. The overall complication rate was 52-59%, depending on the primary 
treatment arm. The rate of pharyngocutaenous fistulae was 15-30%. The 2-year OS 
varied between 69-76%. Van der Putten et al. (118) reported similar results in 
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patients who had received RT or CRT as their primary treatment for LSCC. The pre-
treatment T class was somewhat lower; T1-2 tumors comprised 68% of patients. A 
pharyngocutaneous fistula rate of 30% and an overall complication rate of 56% were 
observed. The 5-year OS was 50% and DSS 58%. Comparable outcomes were 
reported in another study by Li et al. (119). However, the evaluation of these results is 
difficult, as they were not stratified according to the extent of the recurrent or 
persistent disease.   
2.2.4.3 Reirradiation 
 
Reirradiation with external beam RT has been investigated as a means for organ-
sparing curative treatment in recurrent head and neck SCC (120-124). The use of 
reirradiation has been limited due to the risk of major toxicity and treatment-related 
morbidity associated with high cumulative radiation doses. Modern RT techniques, 
such as intensity-modulated radiotherapy (IMRT), may reduce the morbidity 
associated with reirradiation, but studies on reirradiation in LSCC remain limited 
(125,126). In a series consisting of 35 patients who underwent IMRT reirradiation 
with concurrent chemotherapy for recurrent or second primary head and neck 
cancer, the 1- and 2-year survival rates were 59% and 48%, respectively. The median 
progression-free survival was 1.7 years (127). However, acute toxicity was high; 91% 
of the patients had Grade 3 toxicity and 14% had Grade 4 toxicity. Furthermore, four 
patients died from treatment-related adverse events.  
 
In addition to conventional photon RT, the potential of alternative forms of RT have 
also been investigated in the treatment of recurrent head and neck cancer. In 
brachytherapy, the source of ionizing radiation is brought inside the irradiated area 
via pre-inserted plastic tubes. High doses of radiation may be delivered to the tumor 
with lower expected toxicity. However, reports on brachytherapy are scarce in head 
and neck cancer (and anecdotal in LSCC), perhaps due to the inconvenience of 
catheter placement in this anatomically and functionally challenging area (114,128). 
Proton therapy is one of the more intriguing new forms of RT. Contrary to photon 
RT, where maximum energy hits the surface of the target, energy decreasing with 
depth, in proton radiation, maximum energy may be targeted to the tumor tissue, 
thus reducing toxicity to the surrounding tissues (129). The results of proton therapy 
on head and neck SCC recurrence are promising (113).  
2.3 BORON NEUTRON CAPTURE THERAPY (BNCT) 
One of the more intriguing new methods of RT is boron neutron capture therapy 
(BNCT). This experimental treatment is based on the preferential uptake of 
intravenously infused boron into tumor cells and the neutron capture reaction that 
follows when this tumor is irradiated with epithermal neutrons.  
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Neutron capture reactions are nuclear reactions in which one or more neutrons 
collide with an atomic nucleus to form heavier nuclei. In the boron neutron capture 
reaction (10B(n,α)7Li), neutrons collide with 10B to form 11B, which breaks into high 
linear energy transfer α-particles (4He) and recoiling Lithium-7 nuclei (7Li). A small 
amount of γ radiation is also produced (Figure 1) (17).  
 
Figure 1 Boron neutron capture reaction 
2.3.1 DELIVERY OF BNCT AND CLINICAL APPLICATIONS 
 
From a cancer therapy perspective, the boron neutron capture reaction is appealing. 
The α-particles and recoiling 7Li nuclei have short path lengths of only 5-9μm in 
tissue, limiting the lethal radiation effects only to the cells containing 10B. Epithermal 
neutrons in themselves have very little toxic effect on tissues. Thus, this therapy may 
also be administered to previously irradiated areas. In addition, hypothetically, 
weighted doses as high as 60 Gy may be delivered in only one treatment session 
compared with the 6 to 7 weeks required for the delivery of full-course conventionally 
fractionated RT (130). 
 
During administration of BNCT, an intravenous infusion of 10B in a carrier substance 
is first administered prior to neutron irradiation. The prerequisite of BNCT is the 
preferential uptake of 10B-containing substance by tumor cells. To limit the lethal 
effects to tumor cells, a requirement of a 3-fold uptake (and a minimum 
concentration of 20μg/g in tumor) of 10B by tumor tissue compared to normal tissues 
during the time of neutron irradiation has been accepted. To achieve this, 10B has to 
be infused in soluble boron compounds. So far, two substances, namely 
mercaptoundecahydro-closo-dodecaborate (or boronosodiumhydrate, BSH) and 
more frequently (L)-4-dihydroxy-borylphenylalanine-fructose (or 
boronophenylalanine-fructose, BPA-F) have been used in clinical studies (17). In 
2009, Wittig et al. (131) published the results of an EORTC 11001 trial regarding 
concentrations of BPA-F and BSH in head and neck SCC tissues in patients 
undergoing surgery after BPA-F or BSH infusion and established the favorable 
concentration ratio of either substance between tumor tissue and normal tissue. Due 
to the current lack of means to directly measure 10B levels in tumor tissue during 
treatment, indirect approximations are made based on 10B concentrations in patient 
blood samples after BPA-F/BSH infusion and during the neutron irradiation. Some 
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studies have advocated the potential of positron emission tomography (PET) with 
radioactively labeled boronophenylalanine (18F-BPA), 18F-BPA-PET in treatment 
decision-making and dose planning to evaluate the uptake of BPA-F by tumor tissue 
(132). Thus far, the correlation of 18F-BPA-PET results and tissue 10B concentration 
has not been established.  
 
After BPA-F/BSH infusion, the tumor area is irradiated with neutrons. In the early 
days of BNCT, thermal neutrons were used for irradiation. The limitation of thermal 
neutrons was the inadequate (3-4 cm) tissue penetration, hindering their use in more 
deeply seated tumors (e.g. of the brain), and necessitating an intraoperative 
administration during craniotomy. Later, epithermal neutrons with better tissue 
permeability have been used. The source of the neutron beam has been a fission 
nuclear reactor, although accelerator-based neutron sources for hospital use are 
being developed (17). 
 
Currently, the dosimetry and treatment planning of BNCT is limited to estimations 
relying on indirect methods to assess the 10B concentration in tissues. This has led to 
different centers administering BNCT to establish their individual dose-calculation 
methods, which has produced difficulties in inter-study comparability as well as the 
comparability to photon irradiation  (17). 
 
Clinical applications of BNCT have been pursued since the 1950s, when trials on the 
treatment of glioblastoma patients were conducted in the USA with several different 
boron-carrier substances (17). Since then, Chadha et al. (133), Kawabata et al. (134), 
and Kankaanranta et al. (130) conducted studies of BNCT on glioblastoma patients 
and achieved results similar to conventional therapy. Approximately 100 patients 
have entered these studies. The use of BNCT for metastatic melanoma has also been 
reported (135).  
  
BNCT was administered at the Helsinki University Hospital in collaboration with the 
FiR-1 nuclear reactor in Otaniemi, Espoo until 2012 when the facility was closed. At 
present, BNCT is administered in Japan, Taiwan and Argentina. The estimated price 
of BNCT, including all associated costs, was approximately 28000€ per treatment in 
2012. Currently, an accelerator-based BNCT facility is being established at Helsinki 
University Hospital, making this treatment more readily available for patients. 
2.3.2 BNCT IN THE TREATMENT OF HEAD AND NECK CANCER 
 
The first study reporting the clinical application of BNCT for head and neck tumor 
patients was by Kato et al. (136), reporting six patients who had received BNCT for 
recurrent head and neck cancers (3 SCCs, 2 sarcomas, 1 mucoepidermoid carcinoma). 
Although initial tumor size reduction was observed in all patients, only one patient 
had a sustainable complete response (CR). More recently, updates by the same group 
on their patient cohort have been published (137,138). In the latter report, 62 patients 
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with unresectable advanced or recurrent head and neck cancer patients were 
reported. The presented patients had tumors of different head and neck localizations, 
most commonly oral cavity (39% of patients) and nasal cavity and paranasal sinuses 
(27%). Histological variability was abundant with 12 different histology types, most 
commonly SCC (53%) and melanoma (18%). The patients received 1-5 fractions of 
BNCT. At 6 months post-treatment, 28% of the patients showed CR and 30% partial 
response (PR). The overall response rates for all patients, patients with newly 
diagnosed, unresectable tumors, and patients with recurrent tumors were 58%, 39%, 
and 61%, respectively.  
 
Kankaanranta et al. (139,140) from Helsinki University Hospital conducted the first 
prospective Phase I/II trial on BNCT in the management of 30 patients with 
recurrent head and neck cancer. The patients most commonly had tumors of the oral 
cavity (37%) or nasopharynx (30%), with histologies mainly SCC (80%) or adenoid 
cystic carcinoma (13%). The majority of the tumors were advanced, T class 3 or 4 
(60%) but localized (N0, 73%). BNCT was given in two fractions for 26 patients 
(87%); the remaining 4 patients received only one fraction. Treatment response at 3 
months post-BNCT was reported as CR in 45% and PR in 31% of cases, with an 
overall response rate of 76%.  
 
Aihara et al. (141) reported their first experiences of 20 patients with advanced 
primary or recurrent head and neck cancers, which were mostly recurrent SCC (50%) 
and recurrent non-SCC (35%). The sites of the tumors were not stated. They observed 
11 CR and 7 PR responses, amounting to a 90% response rate at 1 month after 
treatment. The 1- and 2-year loco-regional progression-free survival was 60% and 
22%, respectively.  
 
A group from Taiwan reported the results of a Phase I/II prospective study on BNCT 
for head and neck cancer recurring after RT (142). The patients had previously 
received a cumulative photon radiation dose of 63-165 Gy. The majority of the 
patients had tumors of the oral cavity (41%) or nose and paranasal sinuses (24%) 
with main histologic types being SCC (64%) and other carcinomas (29%). Two 
patients received only one fraction of BNCT and the other patients received 2 
fractions. Of the 14 patients eligible for response assessment 3 months after the last 
BNCT fraction, 6 patients showed a CR response. The 2-year locoregional control was 
28%.  
 
In conclusion, head and neck cancers seem to respond to BNCT. However, the 
response is often only partial. Unfortunately, response comparisons between 
different studies are difficult due to various treatment protocols and dose calculation 
methods, as well as the histological, topographical, and classification heterogeneity of 
the tumors. No prospective studies comparing BNCT with conventional treatment 
modalities have been presented.  
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2.3.3 TOXICITY OF BNCT IN HEAD AND NECK CANCER TREATMENT 
 
Traditionally, conventional photon reirradion is considered to carry an unacceptably 
high risk of late morbidity (143). BNCT, hypothetically producing a high radiation 
gradient between tumor tissues and adjacent tissues, has been investigated as a 
means to deliver lethal doses of radiation to the tumor tissue while minimizing the 
toxicity to adjacent tissues. Studies on BNCT for head and neck cancer may be 
divided into those presenting both newly diagnosed and recurrent cancers (136-
138,141), and those only presenting cancer recurring after previous photon RT  
(139,144-146). This heterogeneity makes it somewhat difficult to compare toxicity 
outcomes between different studies.  
 
Similar to RT toxicity in general, toxicity in BNCT studies is graded according to the 
Common Terminology Criteria for Adverse Events: 0, no adverse event or within 
normal limits; 1, mild adverse event; 2, moderate adverse event; 3, severe and 
undesirable adverse event; 4, life-threatening or disabling adverse event; 5, death 
related to adverse event. In the study by Suzuki et al. (138) the most common adverse 
event was transient Grade 3 or 4 hyperamylasemia (27% of patients). Other reported 
toxicities included mucositis (10%), pain (10%), and fatigue (7%). Three patients (3%) 
presented with life-threatening carotid hemorrhage, a condition that may also occur 
irrespective of treatment in some advanced cases. Two of these patients died from 
carotid rupture. In the study by Aihara et al. (141), no toxicity higher than Grade 2 
was reported. In the prospective trials by Kankaanranta et al. (139,140) and Wang et 
al. (145,146), the most common acute Grade 3 toxicity was mucositis (29% and 53%, 
respectively). In the former, other common (at least one third of patients) Grade 3 
toxicities were also noted: oral pain (53%) and fatigue (33%). The latter reported no 
other common Grade 3 toxicities. Grade 4 toxicity was reported in only one patient 
(carotid hemorrhage and laryngeal edema) in the latter trial and in none in the 
former.  
2.4 MARKERS FOR PREDICTING TREATMENT RESPONSE 
AND PROGNOSIS  
2.4.1 GENERAL CONSIDERATIONS 
 
RT is an integral part of LSCC treatment, either in the post-operative setting or as the 
definitive treatment with curative aim. RT can be administered with or without 
chemotherapy. Chemotherapy is most often administered concurrently with RT. 
Curatively aimed oncological treatment carries the potential for organ and function 
preservation even in the case of selected advanced tumors. Although this organ-
sparing approach is generally successful, some patients experience disease 
persistence after therapy or even disease progression, leading to the need for salvage 
surgery. In addition, clinically undetectable, radioresistant tumor cell populations 
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may lead to later recurrence with greater tumor mass (147), thus necessitating TL. If 
radioresistance could be assessed prior to treatment, these patients could be directed 
to surgical therapy with the hope of better outcome. Currently, there are no reliable 
means to assess radioresistance or to predict treatment outcome to guide treatment 
decisions, although several tools have been investigated.  
 
Epidermal growth factor receptor (EGFR), a member of the tyrosine kinase 
transmembrane receptor family, is one of the most researched markers for 
radioresistance and poor prognosis in head and neck SCC. EGFR mediates the 
actions of epidermal growth factor (EGF), ultimately leading to increased cell 
proliferation (148). RT induces the autophosphorylation of EGFR, leading to a 
ligandless activation of the receptor. The resultant increase in cell proliferation (i.e. 
repopulation) counteracts the tumoricidal effects of RT (149). Overexpression of 
EGFR is established as a poor prognostic marker in head and neck SCC (150) and in 
LSCC (151). Cetuximab, a monoclonal antibody targeting EGFR, was investigated 
with RT by Bonner et al. in a randomized trial on advanced head and neck SCC 
patients. They found that the addition of cetuximab to RT was associated with 
improved LC and reduced mortality (152). In their later study, however, no clear 
improvement in larynx preservation could be observed with the addition of 
cetuximab to RT (153).  
 
In addition to cancer cell repopulation, cell hypoxia has been identified as one of the 
main culprits for RT failure. The effect of photon irradiation is delivered to the 
recipient cells via the formation of free radicals within the cells upon irradiation. 
These free radicals, short-lived and highly reactive, in turn induce DNA double-
strand breaks, which are lethal to the cell. Oxygen interacts with free radicals to 
prolong their lifetime and thus increases the damage evoked by them. In hypoxic 
tumor cells, this oxygen interaction is insufficient, which has been shown to increase 
the radioresistance of these cells three-fold compared to adequately oxygenated cells  
(154). 
 
Hypoxia elevates the expression of several proteins in the affected cells, including 
Hypoxia-inducible factor alpha (Hif-1-α), which in turn increases the expression of 
carbonic anhydrase IX (CA-IX) and glucose transporter type 1 (GLUT-1). Hif-1-α is 
encoded by the HIF1A gene and regulates adaptive mechanisms to cell hypoxia (i.e. 
angiogenesis and regulation of cell metabolism and pH), attempting to prevent cell 
death (154). Schrijvers et al. (155) investigated the predictive value of Hif-1-α, CA-IX, 
and Glut-1 in a population of 91 patients who had received definitive RT for T1-T2 
glottic LSCC. In their study, the expression of Hif-1-α and CA-IX, separately and 
combined, were identified as independent predictors of local recurrence. Patients 
with low expression of both Hif-1-α and CA-IX had a significantly lower local 
recurrence rate than patients who had overexpression of at least one of these markers 
(6% vs. 32%; p=0.004). Glut-1 did not show predictive value. In a study by Kwon et 
al. (156), increased expression of Hif-1-α or CA-IX were associated with residual 
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tumor after RT for T1-T2 glottic LSCC but not with local recurrence. Another study 
found no predictive role for these factors in supraglottic LSCC (157). 
 
A variety of other potential predictive markers for treatment response have been 
investigated. Among these are proteins associated with cell damage repair and 
apoptosis, namely survivin, Wrap53β, and p16INK4a.  
2.4.2 SURVIVIN 
 
Survivin is the smallest protein in the IAP family. As RT and chemotherapy are 
believed to trigger apoptosis in cancer cells, IAP poses an interesting target for 
research on radioresistance. Survivin is expressed in most human tumor cells, 
whereas its expression is rarely detectable in normal, matured cells. Survivin plays an 
important role in the regulation of cell division and apoptosis (158). In vitro studies 
on survivin expression and radiosensitivity of tumor cells are contradictory. Some 
studies reported increased radioresistance with increased expression of survivin in 
pancreatic cancer cell (159) and LSCC cell lines (12), while other studies have shown 
an association between radioresistance and survivin downregulation (160). Sun et al.  
(161) examined the functions of survivin in vitro in an oral SCC cell line by knocking 
out survivin with survivin siRNA. Survivin silencing decreased tumor cell growth and 
rendered the cells more sensitive to RT. Survivin silencing also enhanced apoptosis.   
 
Engels et al. examined the localization of survivin expression with regard to 
treatment outcome (162). They concluded that predominantly cytoplasmic survivin 
(in contrast to nuclear survivin) mediates protection against treatment-induced 
apoptosis, thus worsening treatment response.  
2.4.3 WRAP53β  
 
Wrap53 is a gene located on chromosome 17p13. It partially overlaps the tumor 
suppressor gene p53. Antisense RNA produced by Wrap53 regulates the functions of 
the p53 gene. (163) The protein transcripts of the Wrap53 gene include 
Wrap53α, Wrap53β, and Wrap53γ.  Wrap53α stabilizes p53 mRNA, inducing protein 
p53 in response to DNA damage, thus mediating apoptosis. The functions of 
Wrap53γ are currently unclear (164). 
 
The Wrap53β protein is the focus of research regarding the Wrap53 gene. Its 
established functions include trafficking of molecules, such as telomerases to the 
Cajal bodies, which are sub-organelles associated with RNA production.  Wrap53β 
also has a crucial role in telomere elongation, DNA double-strand break repair, and 
ribonucleoprotein biogenesis. Disruption of Wrap53β functions is recognized as a key 
factor in the pathogenesis of dyskeratosis congenita, a condition that predisposes to 
the development of multiple malignant tumors, and spinal muscular atrophy. The 
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role of Wrap53β in the development of cancer is two-fold. On one hand, the Wrap53 
gene functions as a tumor suppressor gene. On the other hand, Wrap53β has also 
been shown to possess oncogenic properties (164). 
 
The expression of Wrap53β has been studied in several different cancer types. 
Diminished nuclear expression of this protein is associated with poor survival in head 
and neck SCC (13), breast cancer (165), ovarian cancer (166), and colorectal cancer 
(167). No specific reports exist on Wrap53β expression in LSCC.  
2.4.4 P16INK4A 
 
Increasing evidence has been presented on the role of high-risk strains of HPV 
(especially 16 and 18) on the pathogenesis of head and neck carcinoma (168,169). 
HPV DNA integration into the genome of mucosal epithelial cells leads to production 
of oncoproteins E6 and E7, both of which inactivate tumor suppressor p53 and 
hinder apoptosis. E7 also binds to the Rb protein, disrupting the E2F/Rb complex, 
leading to the degradation of pRb and eventually removing cell cycle restriction. The 
release of transcription factor E2F induces the overexpression of p16INK4a. This tumor 
suppressor protein, p16INK4a (a biomarker for oncoprotein E7 function), has been 
proposed as a surrogate marker for HPV positivity in tumor tissue with high 
sensitivity. The specificity of p16INK4a in this respect, however, is lower, (170) pointing 
to an additional, HPV-independent route for overexpression of p16INK4a.  
Overexpression of p16INK4a has been demonstrated to predict better treatment 
responses and survival outcomes in patients with oropharyngeal SCC (168,171,172). 
Rieckmann et al. (173) investigated the impact of radiotherapy on five HPV-positive 
and five HPV-negative head and neck SCC cell lines. HPV-positive cells were more 
radiosensitive and exhibited an increased number of residual DNA double strand 
breaks compared to HPV-negative cell lines. Cell cycle arrest or increased apoptosis 
were not observed. Their data suggests that HPV positivity leads to compromised 
DNA repair capability, resulting in better radiosensitivity.  
 
In non-oropharyngeal head and neck carcinomas, the incidence of p16INK4a/HPV 
positivity is generally low (14). Varying degrees of p16INK4a positivity have been 
observed in heterogeneous LSCC patient populations. It has been proposed that HPV 
may play a role in the pathogenesis of LSCC in non-smokers (174) and in younger 
patients (175). HPV may also be more prevalent in female patients or patients with 
regional metastasis (15). However, the role of p16INK4a in predicting treatment 
outcome and survival in LSCC is controversial, possibly due to the rarity of p16INK4a 
positivity in LSCC and the heterogeneity of the existing patient series and 




3 AIMS OF THE STUDY 
The general objective of this study was to assess the current status and outcomes of 
LSCC treatment with curative intent in Finland, focusing on aspects regarding LSCC 
recurrence, the management of recurrent disease, and prognosis after recurrence. 
Based on the relatively poor outcome of patients with T2 tumors, a further aim was to 
explore molecular predictive and prognostic markers for definitive RT/CRT outcome.  
 
The specific aims of the present study were: 
1. To assess the treatment outcome of LSCC in Finland during 2001-2005 in the 
era of definitive CRT. 
2. To assess the clinical risk factors for LSCC recurrence as well as prognosis after 
salvage therapy. 
3. To evaluate the predictive and prognostic potential of survivin, Wrap53β, and 
p16INK4a expression in tumor tissue samples from primary T2N0-T3N0 glottic 
LSCC patients receiving primary oncological treatment.  
4. To evaluate the safety and efficacy of BNCT in the management of recurrent 
LSCC. 
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4 PATIENTS AND METHODS 
4.1 PATIENTS AND STUDY DESIGN 
4.1.1 STUDY I AND II 
 
For Studies I and II, a retrospective patient cohort treated for laryngeal cancer at the 
five Finnish university hospitals during 2001-2005 was gathered. This patient cohort 
comprised of 366 patients who were diagnosed with a new primary laryngeal cancer 
during 2001-2005 and who received their primary treatment (including primary 
salvage) at these hospitals. In comparison with the Finnish Cancer Registry (FCR) 
data, this study included 67% of all laryngeal cancer patients registered during the 
study time. When excluding post-mortem diagnoses and patients without histological 
or cytological confirmation of cancer from the FCR data, the coverage increased to 
73%. The current study and FCR cohorts were similar regarding patient age (median 
64 and 65 years, respectively) and the proportion of male patients (93% and 91%, 
respectively). Advanced-stage tumors were overrepresented in the current study 
(46%) compared to the FCR data (29%).  
 
Data were gathered on patient and tumor characteristics as well as treatment and 
follow-up data, including follow-up data from other hospitals if it took place outside 
the university hospitals. Causes of death were provided by Statistics Finland. 
 
The aim of Study I was to assess laryngeal cancer treatment outcomes in Finland 
after entering the era of definitive CRT as a treatment option for advanced LSCC. Due 
to the different prognostic characteristics, tumors with histologies other than SCC as 
well as patients treated with palliative intent were excluded. This left 342 patients for 
the final analyses. Although this approach hindered the assessment of the general 
prognosis of all LSCC patients, this approach was chosen to gain information on the 
efficacy of curatively intended treatment and to also enable better comparability with 
results of international patient series (these series usually report only the outcome of 
patients undergoing curatively intended treatment).  
 
The aim of Study II was to assess factors associated with LSCC recurrence as well as 
the patterns of recurrence and prognosis after LSCC recurrence diagnosis. Patients 
with successful primary treatment were taken under evaluation. Thus, in addition to 
the exclusions in Study I, patients who died of any cause within 3 months of 
treatment as well as those who had uncontrolled disease progression during 




4.1.2 STUDY III 
 
The aim of Study III was to investigate the value of Survivin, Wrap53β, and p16INK4a 
immunohistochemical staining in predicting oncological treatment outcome and 
prognosis in LSCC patients.  
 
To minimize the bias associated with material heterogeneity, only glottic LSCC 
patients with no evidence of metastases (TNM classes T2N0 and T3N0) who had 
received definitive non-surgical primary treatment (RT or CRT) were investigated. 
Nordic collaboration with Linköping University Hospital, Linköping, Sweden and 
Karolinska Hospital, Stockholm, Sweden was pursued; all patients meeting the 
abovementioned inclusion criteria who were treated at these hospitals during 2000-
2009 and for whom biopsy material was available for investigation were included in 
the study. Clinical data were gathered on patient age and gender, histological grade of 
the tumor and TNM classification, primary treatment (RT or CRT) with total 
radiation doses, the dates of treatment completion, possible recurrences, the date and 
cause of death, the date of last follow-up, and the latest follow-up status. 
4.1.3 IMMUNOHISTOCHEMISTRY 
 
After confirmation of tumor tissue presence in the sample, sample sections were 
mounted on positively charged slides. Deparaffinization was performed (Aqua dePar, 
Biocare Medical, USA).  
 
For p16INK4a analysis, the CINtec Histology Kit for detection of p16INK4a with a 
monoclonal mouse antibody (clone E6H4; Mtm laboratories AG, Germany) was used.  
 
For survivin and Wrap53β, sections were pretreated with 10mM citrate buffer (Diva 
Decloaker [Biocare Medical] and DakoCytomation epitope retrieval solution, 
respectively). Thereafter, a peroxidase block was performed. Samples were incubated 
in a 1:400 dilution of polyclonal anti-survivin (Thermo Fisher Scientific, UK) for 
survivin and 1:1000 dilution of rabbit polyclonal anti-WRAP53-483 for Wrap53β. 
Samples were then stained with EnVision System-HRP (DAB) kit (DakoCytomation). 
Sections were counterstained for 1 minute with Tacha’s hematoxylin. Positive 
controls were prepared from biopsy material obtained from patients with high 
survivin and high Wrap53β expression levels as determined in vitro.  
  
One pathologist and two clinicians scored the samples independently without 
knowledge of clinical data. After individual scorings, a consensus meeting was held to 
obtain a consensus score for the cases with scoring disagreements.  
 
P16INK4a was scored for staining intensity in both the nucleus and the cytoplasm as 
follows: none, weak, moderate, and strong staining. In accordance with common 
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practice, the absence of staining or weak staining were considered p16INK4a negative 
and moderate or strong staining p16INK4a positive.  
 
For Wrap53β, the staining intensity and subcellular staining localization were scored 
separately. Due to heterogenous staining pattern of Wrap53β, only the part with the 
highest intensity of staining was evaluated and categorized as follows: no staining, 
weak staining, moderate staining, and strong staining. Absence of staining or weak 
staining was classified as Wrap53β negative. Moderate or strong staining was 
classified as Wrap53β positive. The staining localization within the cell was 
categorized into nuclear staining (predominantly nuclear staining or equal staining in 
the nucleus and cytoplasm), cytoplasmic staining (stronger staining in the 
cytoplasm), or no staining.  
 
Survivin samples were scored separately for staining intensity in both the nucleus 
and cytoplasm. A scoring system identical to that with Wrap53β was used.  
4.1.4 STUDY IV 
 
The aim of Study IV was to assess the safety and treatment outcome of BNCT in 
patients with LSCC persisting or recurring after primary oncological treatment. An 
emphasis was placed on determining if BNCT could be an organ-sparing alternative 
to TL.  
 
All patients who had undergone BNCT for recurrent LSCC at the Helsinki University 
Hospital were retrospectively identified. Data on patient demographics, primary 
tumor classification, and specifics on primary treatment and toxicity were gathered. 
Prospectively gathered data on recurrent tumor characteristics and classification, as 
well as BNCT treatment specifics were analyzed. When possible, response evaluation 
was performed three months after the first BNCT treatment from CT/MRI scans by a 
radiologist utilizing the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1, 
2009 (178). The Common Terminology Criteria for Adverse Events version 3.0 was 
used to assess treatment toxicity (0, no adverse event or within normal limits; 1, mild 
adverse event; 2, moderate adverse event; 3, severe and undesirable adverse event; 4, 
life-threatening or disabling adverse event; 5, death related to adverse event)  (179). 
 
Ten patients with BNCT treatment for recurrent LSCC were identified. One patient 
who had received cetuximab in addition to BNCT and was participating in an ongoing 
study was excluded, leaving nine patients for the final evaluation.  
4.1.5 STATISTICAL METHODS 
 
For studies I-IV, OS, DSS, DFS, and recurrence-free survival (RFS) were calculated 
with the non-parametric Kaplan-Meier product limit estimate method. A detailed 
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account on the method of calculation of each outcome variable is presented in the 
original publications. Significances of differences between survivals according to 
examined variables (e.g. treatment) were calculated using the log-rank test. For 
studies II and III, independence of potential variables predicting survival were tested 
with Cox multiple regression analysis.  Results were considered statistically 
significant if p < 0.05. 
4.1.6 ETHICAL CONSIDERATIONS 
 
The Helsinki University Hospital Research Ethics Committee approved all studies in 
this thesis (Dnro HUS429/E06/03, Dnro 35/13/03/04/2009, and Dnro 
60/13/03/02/2013). A research permit was obtained for each study from the 
Helsinki University Hospital Department of Otorhinolaryngology – Head and Neck 
Surgery. For Study III, an approval by the Finnish National Supervisory Authority for 
Welfare and Health was acquired (Dnro THL/264/5.05.00/2015). For Study IV, 
informed consent was obtained in accordance to the Helsinki University Hospital 










5.1 TREATMENT AND OUTCOME OF LARYNGEAL CANCER 
IN FINLAND (STUDY I) 
Over the five-year period of 2001-2005, 366 patients were treated for laryngeal 
cancer at the five Finnish university hospitals. SCC was the dominant histology 
(n=360, 98%). The clinical characteristics and T and stage classifications of the 
tumors are presented in Table 2. The presence of neck metastases is shown in Table 
3. The majority of LSCCs (n=253, 70%) were of glottic origin, the largest single group 
being T1 glottic LSCC with 114 patients (32% of the SCC cohort).  A clear difference in 
stage distribution was noted between glottic and supraglottic patients; 69% of the 
glottic LSCC patients presented with early stage (Stage I-II) tumors, whereas only 
23% of the supraglottic LSCC patients had early stage tumors. The same was true for 
T class distribution; 72% of the glottic LSCC patients and 41% of the supraglottic 
LSCC patients had T1-2 tumors, respectively.  
Table 2. Patient characteristics in Study I.  
                        
Gender, n (%) Male 338 (92) 
Female 28 (8) 
Age Mean 65 years (median, 64; range, 31-89) 
Histology, n (%) 
SCC 352 (96) 
SCC variant 8 (2) 
non-SCC 6 (2) 
Stage and TNM of SCC tumors (n=360), n (%)     
Glottic Supraglottic Transglottic Subglottic 
I 114 (45) 7 (8) 0 (0) 0 (0) 
II 61 (24) 13 (15) 0 (0) 1 (20) 
III 44 (17) 26 (29) 4 (31) 3 (60) 
IV 34 (14) 43 (48) 9 (69) 1 (20) 
T1 114 (45) 10 (11) 0 (0) 0 (0) 
T2 65 (26) 26 (29) 0 (0) 1 (20) 
T3 49 (19) 30 (34) 3 (23) 3 (60) 
T4 25 (10) 23 (26) 10 (77) 1 (20) 
                        





Table 3. Neck metastases in LSCC patients in Study I.  
  Glottic (n=253) Supraglottic (n=89) Subglottic (n=5) Transglottic (n=13) 
  
T1     
n=114 
T2    
n=65 
T3    
n=49 
T4    
n=25 
T1    
n=10 
T2    
n=26 
T3    
n=30 
  T4   
n=23 
T2-4            
n=5 
T3-T4              
n=13 
N0 (n=291) 114 62 40 16 7 13 16 9 5 9 
N+ (n=69) 0 3 9 9 3 13 14 14 0 4 
Metastasis rate, % 0 5 18 36 30 50 47 61 0 31 
                      
Abbreviations: N0, no neck metastasis; N+, clinical neck metastasis.  
 
Altogether 342 patients received treatment with curative intent (95%). Treatment 
varied according to tumor stage and localization and is summarized in Table 4.  
Table 4. Treatment of LSCC with curative intent according to T class in Study I. 
                  
  n (%) RT CRT Sx RT/CRT+Sx 
Glottic T1a 33 (36) 0 (0) 52 (57) 7 (8) 
T1b 16 (73) 0 (0) 4 (18) 2 (9) 
T2 48 (77) 4 (7) 3 (5) 7 (11) 
T3 10 (22) 18 (40) 6 (13) 11 (25) 
T4 3 (13) 6 (26) 2 (9) 12 (52) 
Supraglottic T1 4 (40) 0 (0) 2 (20) 4 (40) 
T2 6 (25) 6 (25) 1 (4) 11 (46) 
T3 4 (14) 10 (36) 2 (7) 12 (43) 
T4 1 (5) 8 (36) 2 (9) 11 (50) 
Transglottic T3-4 0 (0) 2 (20) 1 (10) 7 (70) 
Subglottic  T2-4 2 (50) 0 (0) 0 (0) 2 (50) 
                  
Abbreviations: n, number of patients; RT, radiotherapy; CRT, chemoradiotherapy; Sx, surgery. 
 
 
The 5-year DFS, DSS, and OS for LSCC patients treated with curative intent were 
76%, 80%, and 63%, respectively. The results stratified according to tumor 
localization and T class are summarized in Table 5. DSS in both T2 glottic and 
supraglottic tumors was worse than in T3 tumors. As a subgroup, only one of the six 






Table 5. Treatment outcome of LSCC patients according to T class in Study I. 
    5-year survival, % 
    DFS DSS OS 
Glottic T1a 88 100 92 
T1b 82 95 77 
T2 62 78 59 
T3 57 79 64 
T4 51 53 42 
Supraglottic T1 69 68 50 
T2 46 54 33 
T3 63 72 43 
T4 60 59 50 
Transglottic T3-4 70 62 40 
Subglottic  T2-4 0 50 0 
          
Abbreviations: DFS, disease-free survival; DSS, disease-specific survival; OS, overall survival.   
 
5.2 PREDICTORS AND OUTCOME OF RECURRENT LSCC 
(STUDY II) 
For Study II, 316 patients (294 male, 22 female; mean age 64 years, range 32-88 
years) who successfully completed their primary LSCC treatment and who were 
without recurrence at 3 months after the end of treatment were extracted from the 
patient cohort of Study I. The demographics of this patient population are 
summarized in Table 6.   
 
LSCC recurred in 68 patients (22%). The median time to recurrence was 9 months 
(range, 3-59 months). The majority of the recurrences (91%) occurred within 36 
months of the primary treatment. None of the patients with T1a glottic LSCC 
experienced recurrence after 36 months of post-treatment follow-up. In glottic LSCC, 
84% of the recurrences were isolated local recurrences, whereas for other sites, 
(supraglottic and subglottic), this figure was only 30%.  
 
The results of the multivariate analysis regarding factors related to higher risk of 
recurrence are summarized in Table 7. WHO performance status >0, presence of 
neck metastasis at diagnosis, and non-surgical primary treatment were significant 
predictive factors for recurrence in general. In addition, WHO performance status >0 
(hazard ratio 2.9) and non-surgical primary treatment (hazard ratio 2.4) were 
identified as independent predictive factors for local recurrence. Female gender 
(hazard ratio 5.3) and non-glottic tumor localization (hazard ratio 4.9) were 






Table 6. Patient demographics for Study II.  
Characteristic   No. of patients % of patients 
WHO performance status 
0 72 23 
1 212 67 
2-4 13 4 
Missing 19 6 
Localization 
Glottic 231 73 
Other 85 27 
Histological grade 
I 105 33 
II-III 159 50 
Missing 52 17 
T classification 
T1-2 203 65 
T3-4 113 35 
N classification 
N0 270 85 
N+ 46 15 
Stage 
I-II 190 60 
III-IV 126 40 
Treatment 
Sx 73 23 
RT 113 36 
CRT 49 16 
  Sx+RT/CRT 81 26 
Abbreviations: Sx, surgery; RT, radiotherapy; CRT, chemoradiotherapy.  
The WHO performance status grades: 0, Fully active, able to carry on all pre-disease 
performance without restriction; 1, Restricted in physically strenuous activity but ambulatory 
and able to carry out work of a light or sedentary nature; 2, Ambulatory and capable of all self-
care but unable to carry out any work activities. Up and about more than 50% of waking hours; 
3, Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4, 











Table 7. Univariate and multivariate analyses of factors predicting laryngeal squamous 
cell carcinoma recurrence in Study II. 
    recurrence, % p, univariate p, multivariate HR (95% CI) 
Age  
<60 24 n.s. n.s.  ≥60 20 
Gender  
male 20 0.022 n.s.  female 41 
WHO 
0 14 0.051 0.037 2.1 (1.0-4.3) 
1-4 25 
Localization 
glottic 21 n.s. n.s.  other than glottic 24 
Histological grade 
I 21 n.s. n.s.  II-III 23 
T classification 
T1-2 20 n.s. n.s.  T3-4 24 
N classification 
N0 20 0.111 0.018 2.7 (1.2-6.2) 
N1-3 30 
Primary treatment 
non-surgical 26 0.040 0.008 2.2 (1.2-3.9) 
includes surgery 17 
Significant p-values (<0.05) are shown in boldface. Abbreviations: N0, no nodal metastasis; N+, nodal 
metastasis; yrs, years; HR, hazard ratio; CI, confidence interval, n.s., non-significant; WHO, WHO 
performance status. Values with p>0.1 are marked n.s.  
 
Treatment was given with curative intent to 47 patients (69%) for the first recurrence.   
Survival after the first recurrence depended on the localization of the primary tumor 
and the localization of recurrence. Patients with recurrence of non-glottic LSCC had a 
significantly shorter mean survival than patients with recurrence of glottic LSCC (14 
vs. 74 months; p<0.001). Patients with regional/distant recurrence(s) had a 
significantly shorter mean survival compared to patients with only local recurrence(s) 
(8 vs. 83 months; p<0.001). Only 4 out of the 16 patients with subsequent second or 
third recurrences were disease-free at the end of follow-up.   
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5.3 SURVIVIN, WRAP53β  AND P16INK4A IN PREDICTING LSCC 
TREATMENT RESPONSE AND RECURRENCE (STUDY III) 
Tissue samples and clinical data were available for 149 consecutive patients treated 
with RT/CRT for glottic T2N0 or T3N0 LSCC during 2000-2009 (Helsinki University 
Hospital, n=64; Karolinska University Hospital, n=75; Linköping University 
Hospital, n=10). The median age of the patients was 63 years (range, 26-93 years). 
Patient demographics and treatment characteristics are shown in Tables 8 and 9.  
Table 8. Patient demographics for Study III (modified from Study III). 
Characteristic   No. of patients % of patients 
Age <60 years 58 39 
≥60 years 91 61 
Gender Male 143 96 
Female 6 4 
Smoking Ever 128 86 
Never 10 7 
N/A 11 7 
Histological grade I 33 22 
II 82 55 
III 16 11 
N/A 18 12 
T class T2N0 105 71 
  T3N0 44 30 
Abbreviations: N/A, not available.  
 
Table 9. Treatment characteristics of patients in Study III (modified from Study III). 
Characteristic No. of patients % of patients 
Treatment T2N0 RT 94 90 
CRT 11 10 
T3N0 RT 22 50 
CRT 22 50 
RT dose <60 Gy 1 1 
60-69 Gy 99 66 
≥70 Gy 49 33 




Regarding clinical treatment outcome, RFS, DSS, and OS for T2N0 patients were 
59%, 92%, and 64%, respectively. For T3N0 patients, the respective figures were 
34%, 71%, and 47%. T3N0 patients treated with CRT had significantly better RFS, 
DFS, DSS, and OS compared to those who received RT. No significant differences in 
outcome were observed regarding treatment with RT or CRT in T2N0 patients. 
 
We analyzed the expression of p16INK4a, Wrap53β, and survivin in tumor samples. 
One of the tumor samples with survivin staining was lost during the staining process, 
leaving a total of 148 samples for examination. All samples stained positive for 
survivin. The majority of the samples, 95, showed predominantly nuclear staining. In 
35 samples, the staining was predominantly cytoplasmic. Equal staining intensity in 
the cytoplasm and nucleus was observed in 18 samples.  No differences in outcome 
measures were detected between negative, positive cytoplasmic, positive nuclear, and 
positive both cytoplasmic and nuclear groups. However, when the outcomes in the 
group with positive nuclear staining were observed, patients with strong nuclear 
staining had a trend towards better DFS than patients with only moderate or weak 
staining (p=0.091).  
 
Regarding Wrap53β, positive staining was observed in 90 of the 149 tumors (60%; 75 
positive nuclear, 15 positive cytoplasmic). When comparing patients with positive 
Wrap53β staining according to different subcellular localizations, those with positive 
cytoplasmic staining had a trend towards worse OS (p=0.056) and significantly worse 
DFS (p=0.022) compared to those with positive nuclear staining. A trend towards 
worse OS (p=0.072) and DFS (p=0.064) was also observed when comparing patients 
with positive cytoplasmic staining to patients with negative staining. Comparisons 
between the positive-staining group as a whole and the negative-staining group 
regarding outcome proved insignificant. No differences in DSS or RFS were observed 
between any of the groups. 
 
P16INK4a positivity was observed in 11 patients (7%). No correlation between p16INK4a 
expression and outcome was observed for the general cohort. Younger patients (<60 
years of age) had a significantly higher incidence of p16INK4a expression than older 
patients (16% vs. 3%; p=0.017). None of the p16INK4a-positive tumors in this younger 
patient population had recurrence compared with the 36% recurrence rate observed 
in p16INK4a-negative tumors (p=0.041). A significant 5-year DFS advantage (100% vs. 
50%; p=0.021) in favor of patients with p16INK4a-positive tumors was observed. No 
significant differences were observed in OS (100% vs. 68%; p=0.083) or DSS (100% 
vs. 86%; p=0.276).  
 




5.4 BNCT IN THE TREATMENT OF RECURRENT LSCC 
(STUDY IV) 
Ten patients were treated with BNCT at Helsinki University Hospital. The treatments 
took place during 2006-2012. Patients were treated for persistent (n=3) or recurrent 
(n=7) LSCC (Study IV, Table 1). One patient was excluded from the analysis due to 
participation in an unpublished, prospective study concerning adjuvant therapy with 
BNCT, leaving nine patients (8 male, 1 female) for analysis. The median age of the 
included patients was 68 years (mean 66 years; range 51-81 years). All patients had 
previously received photon irradiation to cumulative doses of 38-72 Gy. Seven 
patients were considered to be TL candidates and two were considered inoperable. 
BNCT was administered in 1-2 fractions. When two fractions were delivered, the 
second fraction was administered 1-2 months after the first fraction. The average 
weighted gross tumor volume BNCT dose was 22-38 Gy per fraction. The ranges of 
maximum weighted mucosal dose and maximum weighted skin dose were 5-14 Gy 
and 5-12 Gy.  
 
All except one patient survived at least 3 months after the first BNCT and were 
eligible for toxicity and response evaluations. Five patients (63%) had early (<90 days 
after treatment) Grade 3 toxicity: 3 patients each (38%) had stomatitis, fatigue, and 
oral pain, and 2 patients (25%) had mucositis. Three patients had late Grade 3 
toxicity (38%): two patients had oral pain and one patient each had pharyngeal 
mucositis, stomatitis, and tumor bleed. No Grade 4 or 5 (life-threatening or lethal) 
toxicity was observed. 
 
Eight patients were evaluable for treatment response 3 months after the first (or only) 
fraction of BNCT. Two patients achieved CR and an additional four patients achieved 
PR, amounting to an overall response rate of 75%. The median time to progression of 
the tumor within the target volume was 6.6 months (3.9-8.3 months).  
 
 
Figure 2 Left: A recurrent supraglottic LSCC detected 18 months after full-dose concomitant 




Figure 3 Left: An inoperable LSCC neck metastasis after total laryngectomy, neck dissection and 




Being one of the most studied subsites of head and neck SCC (Pubmed, September 
13th 2016, ”laryngeal” AND ”squamous cell carcinoma”, over 9000 references), there 
are still unanswered questions regarding the ideal choice of treatment, treatment 
outcome prognostication, and management of recurrences in LSCC. Although often 
cited as the one of the most common presentations of head and neck SCC, LSCC is 
divided into clinically distinct subclasses (glottic, supraglottic, subglottic) with 
different propensity for local spread and metastatic potential, and different treatment 
approaches and prognosis. Due to the complexity of LSCC classification (a sum of 
clinical, radiologic, and functional findings), LSCC classification itself poses a 
potential pitfall for comparisons between different studies that often address a 
specific group of patients in a retrospective manner, subject to selection bias. An 
attempt was made in this study to overcome these issues by investigating a national, 
unselected cohort of LSCC patients treated under uniform guidelines (Study I and II), 
a selected, consecutive group of LSCC patients with uniform treatment (Study III), 
and a novel treatment targeted specifically at tumor recurrence after previous 
RT/CRT (Study IV).  
6.1 STUDY STRENGTHS AND LIMITATIONS 
For Studies I and II, all consecutive LSCC patients treated at the five University 
Hospitals in Finland were analyzed. As the treatment of LSCC is centralized in these 
hospitals and a uniform national treatment protocol is followed at these institutions, 
the current status of LSCC treatment in Finland could be reliably assessed. However, 
when comparing the number of patients to those from the FCR, only 67% of the 
patients registered with LSCC during the study period could be found from the 
University Hospital registries. Excluding post-mortem diagnoses and unconfirmed 
histology or cytology from the FCR data increased coverage to 73%. Similar age and 
gender distributions between FCR and the current data were observed. However, 
advanced Stage (Stage III-IV) patients were overrepresented in the current data. This 
confirms the practice of treating a considerable proportion of early stage tumors in 
non-university hospitals, despite the recommendation for centralizing treatment of 
LSCC to university hospitals in Finland. However, as the current material includes all 
patients treated at the University Hospitals following the same Finnish treatment 
recommendations as other centers, reasonably firm conclusions on the status of 
current curatively intended LSCC treatment in Finland can reliably be drawn.  
 
In Study II, only patients with initial successful treatment (defined as the patient 
being alive and without clinical residual disease at 3 months after treatment) were 
included. Patients with persistent tumors after all treatment and those who had died 
during or immediately following treatment were excluded. This may have led to the 
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exclusion of the “worst patients” from the material, thus improving recurrence 
figures. However, the scope of this study was to concentrate on the events during 
patient follow-up and the prognostication of recurrence after successful therapy. 
Therefore, this approach is justifiable.  
 
For Study III, another population of patients and tumor samples was gathered in 
collaboration with Helsinki University Hospital, Karolinska University Hospital, and 
Linköping University Hospital. A fairly large material of tumor samples and clinical 
data (n=149) of uniform tumors (glottic T2-3N0 LSCC) with uniform treatment (RT 
or CRT) was gathered. This inclusion of such a large, highly specified group of 
patients with the elimination of some confounding factors related to tumor site, 
classification, and treatment is scarce in the literature concerning HNSCC 
prognostication with molecular markers. However, the decision to include only 
patients with RT or CRT as primary treatment carries a potential for patient selection 
bias; the patients receiving surgery for glottic T2-3N0 LSCC may have been different 
from the current material regarding some demographic or tumor-related factors. 
Nevertheless, this feature of the material did not hinder the pursuit of the main 
objective of the study, that is, the prognostication of non-surgical treatment outcome 
in glottic T2-3N0 LSCC. Despite limitations associated with its subjectivity, 
immunohistochemistry has proven its usefulness in clinical practice for many tumors. 
However, the assessment of staining intensity is subjective and prone to bias. The 
heterogeneity of protein expression in tumor material and the variable size of the 
examined specimens posed another source of potential bias for the assessment of the 
percentage of tumor cells with protein expression. Having three independent 
examiners score the samples without knowledge of clinical data minimized this bias.   
 
In Study IV, a small cohort of patients receiving BNCT for recurrent LSCC was 
examined. Although done in a larger prospective BNCT study setting, the majority of 
patients in this study were treated as so-called compassionate cases with the 
associated lack of some follow-up data characteristics (e.g. one patient lacked the 
proper response evaluation MRI at 3 months after BNCT). Despite this weakness, 
response assessment could be conducted on all but one patient (one patient died one 
month after the treatment). The major goal of treatment safety assessment was 
achieved by clinical record review as well as from the CTCAE forms that had been 
completed during each visit. Although the number of patients in this study was small, 
it is the first published study concerning BNCT in a specific locational (larynx) and 
histologic (SCC) subgroup of head and neck cancer. It is also the first study 
examining BNCT as a potentially larynx-sparing treatment for radiorecurrent LSCC.   
 
Regarding boron uptake by the tumor, to date no reliable direct standard method 
exists for its assessment. In the current study, the tumor to normal tissue ratio of 3.5 
was assumed based on previous studies (180). This possible inaccuracy of boron 
concentration assessment made it challenging to evaluate the administered BNCT 
dose. Therefore, it is difficult to say whether incomplete treatment responses were 
due to insufficient boron uptake or other factors.  
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6.2 LSCC IN FINLAND 
6.2.1 TREATMENT AND OUTCOME (STUDY I) 
 
Nationwide studies on the treatment of LSCC are rare. In Studies I and II, a 
nationwide five-year cohort of LSCC patients was examined for subsite and stage 
distribution, treatment outcome, recurrence, and ultimate survival. In agreement 
with the current study, the glottis is widely observed as the most common subsite of 
LSCC (24,181,182), although some have observed supraglottic predominance (183).  
Mäkitie et al. (22) observed a change in subsite distribution from supraglottic 
predominance (65%) to glottic predominance (70% in the current series) in Finland 
over the last decades of the 20th century. The reason for this was speculated to be the 
simultaneous decline in alcohol and tobacco consumption over those decades. 
Concurrent with the current findings, subglottic LSCC is recognized as a rare 
localization, comprising approximately 1-2 % of all LSCCs (24,184-187). Similar to the 
current study, Bien et al. (24) reported a predominance of T1-2 tumors (54%) in the 
glottic subsite and predominance of T3-4 tumors (68%) in the supraglottic subsite. 
This difference in stage distribution between glottic and supraglottic tumors may be 
explained by variations in symptom profile: glottic tumors lead to hoarseness early on 
in their course, whereas patients with supraglottic tumors may remain asymptomatic 
longer.  
 
An excellent treatment outcome for glottic T1 LSCC with either TLS or RT was 
observed. Similar results with TLS or RT have been presented in numerous studies 
(47-49,52,57-59,188). Several authors have claimed an increased laryngeal 
preservation rate in patients treated with TLS compared with RT (57-59). However, 
these findings come from retrospective series prone to patient selection bias; more 
deeply infiltrating tumors with greater risk for recurrence may have been treated 
preferably with RT. Recent systematic reviews regarding the treatment choice for 
glottic T1 LSCC have found no evidence to support one treatment approach over 
another (60,189). Aaltonen et al. (61) reported differences in voice breathiness in 
favor of RT in a randomized trial of 60 patients comparing RT and TLS in the 
management of T1a glottic LSCC. A meta-analysis by Higgins et al. also noted the 
superiority of RT over TLS regarding voice outcomes (190). However, in a prospective 
cohort study of 106 patients (TLS, n=67; RT, n=39), van Gogh et al. (191) noted faster 
voice recovery in patients treated with TLS regarding jitter, shimmer, and noise 
energy. They concluded with a recommendation of TLS over RT in the management 
of T1a glottic LSCC.  
 
One of the advantages of TLS over RT is the shorter time spent in treatment. TLS is 
ideally a one-session treatment while a full-course RT usually takes 6-7 weeks. 
Regarding treatment cost (including the hidden cost of missed work hours), TLS 
appears less expensive (192,193). The vast retrospective evidence shows similar, 
excellent oncological outcomes with either treatment, yet somewhat conflicting voice 
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outcome results.  Large, prospective trials with adequately long follow-up are needed 
to find potential differences between treatments regarding long-term adverse effects 
(including potential second malignancies following RT for LSCC), voice outcome, and 
quality of life.  
 
In this study, both glottic and supraglottic T2 tumors had remarkably poorer 
treatment outcome than expected. As early T class tumors, one would expect the 
outcomes to be closer to T1 tumors and not T3 tumors as was observed in the current 
study. Most of the glottic T2 patients received RT (77%) or CRT (7%) as their only 
primary treatment. In the supraglottis, T2 tumors had the worst outcome among all T 
classes. Half of these patients received RT or CRT as their primary treatment. 
Unfortunately, due to the relatively small size of these sub-cohorts, comparisons 
between treatment approaches (non-surgical vs. surgical) could not be conducted. A 
recent study based on the Surveillance, Epidemiology, and End Results (SEER) 
database (194) examined the treatment outcomes of Stage I (T1N0) and Stage II 
(T2N0) glottic LSCC. Significantly poorer DSS for Stage II patients was observed 
compared to Stage I patients (94% vs. 87%; p<0.0001), despite the treatment being 
identical for both groups. They concluded that Stage II patients might benefit from 
more aggressive therapy either by combining surgery and post-operative RT or by 
definitive CRT. Study III showed no survival advantage for T2N0 patients treated 
with CRT compared to those who were treated with RT alone. However, the number 
of patients treated with CRT was small. The aforementioned data from SEER also 
included patients (5%) with no treatment. Among these patients, Stage I patients had 
a significantly better DSS than Stage II patients (93% vs. 67%; p<0.0001), suggesting 
a difference in tendency for tumor progression. Haugen et al. investigated the 
feasibility of an accelerated-hyperfractionated RT schedule in the treatment of T2N0 
glottic LSCC (195). In their study, T1N0 glottic LSCC patients were given a total dose 
of 62.4 Gy in once-a-day fractions over 6.5 weeks, whereas T2N0 patients were 
treated with a split-course hyperfractionated-accelerated RT to a total dose of 64.6 Gy 
over 4.5 weeks. The oncological outcome for both groups was similar, indicating a 
potential benefit in shortening the overall treatment time for T2N0 glottic LSCC. The 
merits of accelerated RT are further supported by Overgaard et al. (196), who 
investigated the benefit of giving six fractions per week instead of five in a population 
of 1476 head and neck cancer patients. They observed significantly better LC and DSS 
in the group receiving six fractions per week. OS, however, did not differ between the 
groups. Regarding early supraglottic LSCC, Arshad et al. (197) (also based on SEER 
data) demonstrated superior outcomes with organ preservation surgery compared to 
RT alone, although this study was prone to selection bias due its retrospective nature. 
  
The treatment outcome of advanced glottic and supraglottic LSCC in the current 
material with 5-year DSS of 79% and 72% for T3 tumors and 53% and 59% for T4 
tumors is well in line with other reports describing treatment results of these tumors 
using various surgical and oncological treatment approaches (69,198-201). 
Traditionally, large-volume T4 tumors have been considered unsuitable for definitive 
oncological treatment (202), concurrent with findings from the current study 
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regarding T4 glottic LSCC, although some retrospective reports have challenged this 
principle (203,204). In the early 1990s (2) the concept of tumor response to 
induction chemotherapy was introduced as a method of treatment selection between 
radiotherapy and TL in advanced LSCC. With later results indicating an advantage of 
CRT over induction chemotherapy followed by RT (3), CRT without induction 
chemotherapy was widely adopted as the mainstay of non-surgical treatment in 
advanced LSCC. A recent study by Wolf et al. (205) reported the treatment outcomes 
of an unselected patient series utilizing induction chemotherapy as an individualized 
bioselection between CRT and TL as one of the treatment alternatives. A single cycle 
of cisplatin and 5-fluorouracil was administered to these patients followed by clinical 
treatment response assessment. Patients with tumors responding to induction 
therapy further underwent CRT, whereas patients with non-responsive tumors 
underwent TL. DSS for this bioselection group was superior to the CRT group and 
similar to the TL group. This approach may prove useful in the pursuit of better 
outcomes for organ-preservation therapy in LSCC, although more studies are 
warranted. Recently, new surgical techniques, namely transoral robotic surgery, have 
been introduced for organ-sparing LSCC management, especially in the case of 
supraglottic LSCC, with encouraging results (206,207). 
6.2.2 RECURRENCE (STUDY II) 
 
Despite successful primary treatment, LSCC has a tendency to recur. Recurrence has 
been reported to occur in up to 30% of cases (102-104). Variability in this tendency 
among different tumor stage groups is evident (11). In the current study, only 11% of 
T1 LSCC tumors recurred whereas recurrence was more common (21-39%) in T2-3 
tumors. Other groups have reported similarly low recurrence rates for T1 LSCCs 
(106,208).  
 
Currently, the European Laryngological Society recommends a 5-year post-treatment 
follow-up in LSCC (86). According to numerous studies, the majority of recurrences 
occur within three years of treatment completion and recurrences are rare thereafter 
(11,102,105,209,210). In the current cohort, the median time to recurrence was 9 
months, with only 6 recurrences presenting after 36 months of follow-up. Somewhat 
later recurrences were observed by Canis et al. (106), who reported T1a glottic LSCC 
recurrences to occur as late as 131 months after treatment (median time to recurrence 
34 months).  
  
The advantage of the full 5-year follow-up over shorter follow-up for head and neck 
SCC remains unproven. Pagh et al. (211,212) conducted two cross-sectional studies 
regarding follow-up activities for head and neck SCC patients in Denmark. They 
observed a scarcity of late treatment-related morbidity and recurrences, proposing a 
limitation of routine follow-up to 3.5 years after treatment. They also observed an 
incidence of asymptomatic recurrence of 1 in 99 surveillance visits. Agrawal et al. 
(213) also examined the role of symptoms in the detection of recurrences and 
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observed that 79% of the patients diagnosed with recurrences were symptomatic. 
This rate was even higher (85%) in another study by the same group (214). However, 
73% of these symptomatic recurrences were diagnosed at routine surveillance visits 
rather than at an earlier time point. Thus, anticipation of an upcoming surveillance 
visit may even delay the diagnosis of recurrence.  
  
The utility of surveillance from the oncological point of view is the timely detection of 
treatable recurrences. Matoscevic et al. (215) observed a significantly reduced salvage 
rate for patients having locoregional versus local recurrences of LSCC. Agrawal et al. 
(214) observed significantly better post-recurrence survival for patients with primary 
early stage disease and isolated local recurrence. High salvage rates have also been 
reported for recurrent early LSCCs by TLS (16). The aforementioned results may 
imply that, in fact, the low risk patients may benefit more from follow-up than high-
risk patients. High-risk patients, however, frequently have more treatment-related 
morbidity and need for physiotherapy, speech therapy services, and psychosocial 
support, thus justifying their close follow-up during the first post-treatment years.  
 
A WHO performance status over 0 was found to be an independent predictor of 
recurrence in general and also a predictor of local recurrence in the current study. 
Cuny et al. (7) reported lower RFS for patients with WHO performance status >1. 
These findings were shared by Smee et al. (8), who observed higher incidence of local 
failures in patients “unfit for surgery”, although this factor was only significant in 
univariate analysis. However, when the endpoint was set to ultimate local failure, this 
factor also proved to be an independent prognostic factor. The general health status 
of the patient seems to have an independent impact on disease control, irrespective of 
tumor stage or treatment. Studies supporting the observation of female gender as a 
predictor of regional recurrence could not be found.  
 
Non-glottic (mainly supraglottic) tumor location was also found to be an independent 
factor predicting regional recurrence in the current study. Johansen et al. (11) and 
Brandstorp-Boesen et al. (89) observed similar findings on the impact of tumor 
localization on recurrence (10). The presence of primary nodal metastasis as a general 
predictor of recurrence is supported by several studies, although the observation of 
this presence being an independent predictor of distant metastasis was not made in 
the current study, possibly due to the relatively small number of patients in this 
subgroup (93-95). 
 
The impact of treatment choice on outcome has been one of the main topics of LSCC 
management. While the treatment outcomes in the USA are declining (4) and only 
slightly improving in Scandinavia (5), serious concerns regarding the feasibility of 
organ-sparing therapy have been raised (75-77). In the current retrospective series, 
primary non-surgical treatment was identified as an independent predictive factor for 
recurrence in general and also for local recurrence.  A study based on the Netherlands 
Cancer Institute material revealed a significantly lower recurrence rate for T3-4 LSCC 
patients undergoing TL (13%) compared with those who received RT (32%) or CRT 
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(30%) (66). Although most of the studies addressing this issue are retrospective, it is 
logical to expect better LC after TL. TL may be considered a form of wide-field 
surgery, or even “compartmentectomy” of the entire laryngeal cancer site where 
dysplastic mucosa may be left behind after larynx-sparing treatment. Despite these 
results, there seems to be no difference in survival between the treatment groups. 
 
When LSCC recurs, the most common mode of recurrence is an isolated local 
recurrence, which comprises over 50% of all recurrences (107,110). In this study, 68% 
of the recurrences were in the primary tumor site only. Local recurrences can often be 
successfully salvaged with good prognosis after treatment (118,216-220). Concurrent 
with these findings, a good 5-year post-recurrence DSS of 74% for patients with 
isolated local recurrences was observed in the current study. In contrast, more 
widespread recurrences translated to poor prognosis. Matoscevic et al. (215) also 
reported a drop in 5-year OS from 70% to 20% when locoregional recurrence instead 
of local recurrence only was detected. Brenner et al. (107) reported 2-year survival 
figures of 75% for local, 57% for regional, and 33% for distant recurrences. None of 
the patients with non-glottic tumor recurrence could be permanently salvaged in the 
current material. Sessions et al. (93) noted a similar, poor prognosis for supraglottic 
SCC recurrence, a 5-year DSS of only 17%. These results underline the importance of 
adequately aggressive primary treatment especially in the supraglottic patient group.  
   
6.3 SURVIVIN, WRAP53β ,  AND P16INK4A IN LSCC (STUDY III) 
Currently, no reliable, clinically applicable means exist to stratify LSCC according to 
radiosensitivity. Therefore, it is important to identify an easy to assess, reproducible 
marker (or a panel of markers) with high sensitivity and specificity to enable the 
tailoring of treatment according to radiosensitivity and to achieve better outcomes for 
radioresistant tumors.  
 
In previous studies, strong survivin expression has been associated with improved 
treatment outcome in a group of patients with various types of head and neck SCC 
(160,221). In the current study, with more homogenous patient material of T2-3N0 
glottic LSCC treated with RT or CRT, the association was weaker. Only a trend 
towards better DFS was observed when the patients with positive nuclear expression 
were analyzed separately. A trend for better DFS in patients with strong nuclear 
expression was observed. Survivin expression was more heterogeneous in the current 
study compared to the data by Farnebo et al. (160), where the expression was 
predominantly nuclear. LSCC may present a different survivin expression pattern 
compared to head and neck SCC in general. Marioni et al. (222) studied the role of 
survivin in patients operated for LSCC. In their study, 83 patients with variable 
LSCCs of different T and N classes were assessed for tumor survivin expression. 
Strong nuclear survivin expression was associated with an increased rate of 
recurrence and decreased DFS. They also examined a panel of biomarkers, including 
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survivin, for predicting LSCC recurrence in patients undergoing post-operative RT. In 
their study, nuclear survivin expression was associated with poorer outcomes as well 
(223). This negative predictive role of survivin was also observed by Lo Muzio et al. in 
a series of oral cavity SCC patients (224). Different cellular localization and subtypes 
of survivin may explain these contradictory results (225). These contradictory results 
may also reflect the different treatment approaches across these studies.  
 
In the current study, a trend towards poorer OS and significantly poorer DFS was 
observed for patients whose tumors revealed positive cytoplasmic staining for 
Wrap53β compared to those staining positive in the nucleus or those with negative 
staining. Silwal-Pandit et al. observed a similar poor outcome for breast cancer 
patients with tumors staining positive for Wrap53β in the cytoplasm but negative in 
the nucleus (165). Zhang et al. (226) examined Wrap53β expression in rectal cancer 
patients who were either treated with preoperative RT and surgery or surgery alone. 
Wrap53β downregulation was observed after preoperative RT. In the RT group, 
Wrap53β expression in the primary tumor had no effect on patient survival. However, 
expression of Wrap53β in metastases improved RT outcome. Unfortunately, 
information on the subcellular localization of Wrap53β was not available for 
comparison. The authors proposed that Wrap53β may be associated with the 
apoptotic pathway and Wrap53β downregulation may eventually lead to cell death. 
As the known functions of Wrap53β take place in the nucleus, it has been suggested 
that trapping of Wrap53β in the cytoplasm may hinder these functions, for example 
repair of DNA double-strand breaks (166,227). Wrap53β downregulation in the 
nucleus may also lead to telomere dysfunction, increasing radioresistance (228,229). 
These findings support our observation of cytoplasmic Wrap53β as a negative 
prognostic marker. 
 
In oropharyngeal SCC, p16INK4a positivity has recently been recognized as a marker 
for improved treatment outcome (168,172). This improvement seems to be 
independent of treatment choice (230). However, in other head and neck sites, no 
such clear role for this marker has been shown to date (15,174,175,177). In the current 
study, p16INK4a positivity was rare and was associated with younger age (<60 years). 
In this younger population, no recurrences were detected in patients with p16INK4a-
positive tumors. Similar trends have been reported by some studies (174,175). 
Although not a significant marker in the general population of LSCC, p16INK4a may 
play a role in the pathogenesis and disease course in the subgroup of younger 
patients. While non-smokers had a higher prevalence of p16INK4a positivity in the 
current material, the number of these patients was too small for outcome 
comparisons with smokers.  
 
Contrary to expectations, no associations between the above-mentioned markers and 
the presence of residual tumor after primary treatment could be detected. This may 
be due to the small number of patients having residual tumors after primary 
treatment (9%), which inevitably makes comparisons between protein expression and 
the initial success of therapy statistically insignificant if the association is not very 
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strong. Later recurrences, however, may be due to the proliferation of surviving 
radioresistant tumor cell populations. Accordingly, the assessment of especially DSS, 
DFS, and RFS may be reasonably considered to act as surrogate endpoints for 
radiosensitivity assessment. However, there may yet be some unknown mechanisms 
associated with these markers besides alterations in radiosensitivity that affect these 
outcomes.    
6.4 BNCT IN THE TREATMENT OF RECURRENT LSCC 
(STUDY IV) 
The current study is the first published series examining BNCT in the treatment of 
persistent or recurrent cancer of a single head and neck site with uniform histology, 
namely LSCC. Only two patients were found with LSCC from a previous series 
regarding BNCT in head and neck cancer; no information regarding their individual 
treatment outcomes is available.  
 
The observation of overall response rate (75%) of persistent or recurrent LSCC to 
BNCT in this study is consistent with previous series regarding BNCT for head and 
neck cancer of variable sites and histologies (138,139,141,146,231). Despite initial 
positive treatment responses, durable disease control was achieved in only one 
patient with a small (1.4 cm in diameter) recurrent tumor. Several possible 
explanations for this may be speculated. Firstly, although a small sample size study 
by Wittig et al. exists on BPA-F uptake in head and neck SCC tissue (131), no data 
exists on BPA-F absorption to LSCC tissue in particular. Uptake of BPA-F by LSCC 
tissue may be different from other head and neck tumors, possibly leading to 
inadequate radiation dose. Secondly, dose calculations are difficult due to the lack of 
validated, accurate, and quantitative means to directly monitor BPA-F concentration 
in the tumor tissue itself. This may lead to under- or over-estimations of the delivered 
radiation dose, which can lead to increased toxicity or inadequate dose. Since tumor 
tissue is hard to obtain and analyze during the treatment process, other means of 
dose estimation are being sought. 18F-BPA-PET is often conducted to verify tumor 
loading with BPA-F. However, no knowledge exists on the relation of findings on 
PET-CT scans to the actual concentration of BPA-F in tumor tissue, although PET-CT 
often demonstrates the dualistic accumulation of BPA-F to the tumor tissue while the 
concentration in normal tissues is low (139,232,233). 
 
BNCT for recurrent LSCC was associated with a favorable toxicity profile. No Grade 
4-5 early or late toxicity was observed and overall, acceptable rates of toxicity were 
encountered. This finding is in agreement with previous studies on BNCT in head and 
neck cancer, although other authors have reported some serious adverse effects. For 
instance, Wang et al.  (146) and Suzuki et al. (138) reported incidences of carotid 
blowout after BNCT for head and neck carcinoma in 1 out of 17 and 3 out of 62 
patients, respectively. Only one of these patients survived. Ideally, BNCT targets 
tumor cells sparing the surrounding healthy tissues from increased toxicity associated 
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with high radiation doses. Adverse effects may partly be sequelae of the 
aforementioned inaccurate dose estimations that are currently in use. When 
comparing BNCT to conventional reirradiation, toxicity is similar or lower 
(123,125,126).   
6.5 FUTURE PERSPECTIVES 
LSCC incorporates a wide spectrum of tumors with varying biological behavior and 
treatment strategies. As demonstrated, different treatment approaches may produce 
comparable treatment outcomes for similar TNM class tumors in selected patient 
materials. However, in every subsite and TNM category, excluding T1a glottic LSCC, 
recurrences are common and seriously compromise the goal of a cancer-free, high 
quality of life. With regard to the results of the current study, prospective studies on 
the role of prognostic markers for different treatment approaches (especially non-
surgical treatment) should be conducted on sufficiently homogenous patient 
materials to obtain tools to counteract the observed subpar survival outcomes in 
certain patient groups, e.g. T2 tumors in the current study. Risk-group stratification  
(enabling treatment intensification for high-risk patients) and treatment de-
intensification (to avoid adverse events where possible) would also improve the 
quality of LSCC treatment. Furthermore, follow-up protocols could be tailored to 
meet the individual patient’s risk profile and needs, aiding in directing resources 
more efficiently. This risk-stratification may not necessarily be achieved by solitary 
markers alone (e.g. Wrap53β), but rather with panels of clinical and molecular 
markers. Large-scale, multi-center, and even international studies are needed to 
achieve sufficient numbers of patients for distinct patient subgroups.  
 
Despite future advances in risk-stratification and treatment tailoring, recurrences will 
inevitably continue to present a management challenge in LSCC. TL produces 
favorable outcome but at the expense of laryngeal function. New technological 
advances in laryngeal surgery, e.g. transoral robotic surgery and new functional 
reconstruction techniques, may improve the oncological and functional outcomes of 
organ-sparing laryngeal surgery. New, more targeted forms of RT, e.g. proton therapy 
and BNCT, are being brought into investigational and clinical practice. In BNCT, the 
need for further refinement of the treatment protocol, i.e. more precise dose 
estimation and treatment tailoring, is evident. To achieve this, dynamic boron 
concentration development studies on tumor tissue are needed. Distinct studies 
should be conducted for different tumor sites and histologies, as the development of 
boron concentration in various localizations and histologies may vary. Also, more 
selective carriers for boron other than BPA-F or BSH are needed to optimize the 
tumor-to-tissue concentration ratio to further reduce treatment toxicity and thus 
enable dose escalation.  
 
One of the advantages of BNCT is the ability to deliver high doses of RT over only 1-2 
sessions compared to the conventional RT protocols. As different aspects of BNCT are 
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being explored, the spectrum of BNCT indications may also broaden with time. BNCT 
has already been investigated as a part of the primary oncological treatment (144). 
Although no reports exist so far, BNCT may also be experimented with in the future 
in the post-operative, adjuvant setting for recurrent tumors. With the development of 
clinic-based cyclotrons, epithermal neutrons are becoming increasingly available for 
clinical use in the future, compared to the conventional nuclear reactor source. 
Currently, a BNCT center utilizing this technology is being constructed in Helsinki. 





1. The outcome for T1a glottic LSCC in Finland is excellent. However, the 
outcome of patients with T2 glottic and supraglottic tumors was poorer than 
expected. CRT is increasingly used in the treatment of T3-4 LSCC. For T3 
glottic LSCC, CRT produces better outcomes than RT. Based on the 
experiences from study I, CRT cannot be recommended for glottic T4 patients.  
 
2. LSCC recurrences are rare after 36 months of follow-up, questioning the need 
for the standard 5-year follow-up for all LSCC patients, especially those with 
T1a glottic LSCC. WHO performance status >0, regional metastasis at 
presentation, and non-surgical primary treatment are independent predictors 
of recurrence. Local recurrences after glottic LSCC carry a good chance for 
cure. All other types of recurrences are associated with poor outcome.  
  
3. Predominantly cytoplasmic Wrap53β expression is associated with 
significantly poorer DFS and a trend for poorer OS in T2-T3N0 glottic LSCC 
patients treated with non-surgical therapy. p16INK4a positivity is more 
abundant in younger patients, indicating a possible etiological role for HPV 
and a reduced risk of recurrence in this subgroup.  
  
4. BNCT is safe in the treatment of LSCC recurrence. Although initial tumor 
response to BNCT is common, successful salvage of recurrent LSCC with 
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